Formulation Development and Evaluation of Mycophenolate Sodium 360mg Delayedrelease Tablets by Ananth, R
FORMULATION DEVELOPMENT AND EVALUATION
OF MYCOPHENOLATE SODIUM 360mg DELAYED-
RELEASE TABLETS 
Dissertation submitted to
The Tamilnadu Dr. MGR Medical University, Chennai-32
In partial fulfillment  of the  requirements
for  the award of the degree of
MASTER OF PHARMACY
IN
PHARMACEUTICS
By
 REG. NO: 26113901
Under The Guidance of
Mr. V.  SIVAKUMAR, M.Pharm, 
DEPARTMENT OF PHARMACEUTICS
ARULMIGU KALASALINGAM COLLEGE OF PHARMACY
Anand Nagar, Krishnankovil-626190
APRIL-2013
CERTIFICATE
This  is  to  certify  that  the  dissertation  work  entitled
“FORMULATION  DEVELOPMENT  AND  EVALUATION  OF
MYCOPHENOLATE SODIUM 360mg  DELAYED-RELEASE  TABLETS  ”
was  carried  out  by  Reg.  No:  26113901  in  the  Department  of
Pharmaceutics,  Arulmigu  Kalasalingam  College  of  Pharmacy,
Krishnankovil,  affiliated  to  the  Tamilnadu    Dr  M.G.R  Medical
University,  Chennai.   This   work  was   guided    and   supervised   by  
Mr.V.SIVAKUMAR, M.Pharm, (PhD) Assistant Professor, Department
of  Pharmaceutics.
Date:
Place: Krishnankovil
 
Dr. M. PALANIVELU, M.Pharm, PhD 
                                             Principal,
                                                  Arulmigu Kalasalingam College of Pharmacy,
                                                  Krishnankovil.
                                                                                                     
                                                                        
CERTIFICATE
This  is  to  certify  that  the  dissertation  work  entitled
“FORMULATION  DEVELOPMENT  AND  EVALUATION  OF
MYCOPHENOLATE SODIUM 360mg DELAYED-RELEASE TABLETS” was
carried out successfully by Reg. No: 26113901   in the Department of
Pharmaceutics,  Arulmigu  Kalasalingam  College  of  Pharmacy,
Krishnankovil,  (T.N),  under  my  guidance  and  supervision  during  the
academic year      2012-13.
Date:
Place: Krishnankovil
   Mr. V.  SIVAKUMAR, M.Pharm,
   Assistant Professor,
    Department Of Pharmaceutics,
                                             Arulmigu Kalasalingam College of Pharmacy,
                                                  Krishnankovil.
EVALUATION CERTIFICATE
  This  is  to  certify  that  the  dissertation  work  entitled
“FORMULATION  DEVELOPMENT  AND  EVALUATION  OF
MYCOPHENOLATE  SODIUM  360mg  DELAYED-RELEASE
TABLETS” is submitted by Reg. No: 26113901 to  “The Tamil Nadu
Dr. M.G.R. Medical University,” Chennai, in partial fulfillment of the
requirements for the award of degree of   MASTER OF PHARMACY
in  PHARMACEUTICS  under  the  guidance  and  supervision  of
Mr. V. SIVAKUMAR, M.Pharm.,
Date:
Centre: Arulmigu Kalasalingam College of Pharmacy,
              Anand Nagar, Krishnankoil-626126,
             Virudhunagar District, Tamilnadu.
Examiners:
1.
2.
ACKNOWLEDGEMENT
First and foremost I express my Cordial gratitude to the Almighty
god who helped me to complete my project work. My Endeavour would stand
incomplete without few words of gratitude to the persons who have contributed
much towards the successful completion of the present work.
As I submit the thesis, I am indebted to the priceless grace and
endless mercy of God, the Almighty. 
I  owe  my  cordial  gratitude  to  my  guide
Mr.  V.  SIVAKUMAR  M.Pharm.,  Assistant  Professor,  Department  of
Pharmaceutics,  Arulmigu  Kalasalingam College  of  Pharmacy,  who  was  the
core  and  source  of  all  encouragement,  inspiration  and  guideline  in  the
endeavour.     
  
I  would  like  to  express  my  heartful  thanks  to
Dr. M. PALANIVELU M.Pharm., PhD, Principal, Arulmigu Kalasalingam
College of Pharmacy, for their immense support. 
I  thankfully  acknowledge  the  unreserved  encouragement,
timely  help  and  valuable  suggestions  rendered  to  me  by
Mr.  K. ANANDA RAJA GOPAL  M.Pharm.,  Assistant  Professor,
Department of Pharmaceutical Chemistry, Malaysia.
I  owe  my  deep  gratitude  to  Prof.  G. VINOTHAPOOSHAN
M.Pharm., (PhD),  Assistant  Professor,  Department  of  Pharmaceutics,
Arulmigu Kalasalingam College of Pharmacy, who was the core and source of
all encouragement, inspiration and guideline in the endeavour.
                 I express my heartfelt gratitude Dr. P. BHARATHIDHASAN,
M.Pharm,  PhD professor,    Department  of  Pharmaceutics,  Arulmigu
kalasalingam College of Pharmacy, for their immense support.
I am also thankful for the support and suggestions given to me by
Dr.  J.  JAYA  ANANTHI  M.Pharm.,  PhD  Department  of  Pharmaceutics,
Arulmigu kalasalingam College of Pharmacy            
I  take  this  opportunity  to  express  my  sincere  thanks  to  the
Mr. JERRIN  VINCENT  M.Pharm,  Deputy  Manager,  Formulation  R&D,
Bafna pharmaceutical Ltd., Chennai for providing drug samples.
 I also express gratitude to  Mr. E. GOVINDARAJAN M.Sc.,
Senior Executive, Analytical R&D, Bafna Pharmaceutical Ltd., who took the
full effort and helped me in carrying out the Dissolution studies successfully.
I  gracefully  acknowledge  the  co-operation  rendered  by
Mr. R. BALAMURUGAN, Librarian, which enabled me to utilize the library
facilities for my project purpose.
I also extend my whole hearted thanks to my classmates whose
suggestions and help were of great use during the present study.
CONTENTS
     PAGE NO
CHAPTER-1
              INTRODUCTION 1
CHAPTER-2                                                                     
                REVIEW OF LITERATURE 23
CHAPTER-3                     
                AIM AND OBJECTIVE 34
CHAPTER-4                                                                     
                PLAN OF WORK 35
CHAPTER-5                                                                     
                DRUG AND EXCIPIENTS PROFILE 36
CHAPTER-6                                              
                  MATERIALS AND METHODS 67
CHAPTER-7
RESULTS AND DISCUSSION 89
CHAPTER-8    
          SUMMARY AND CONCLUSION           118
CHAPTER-9    
           BIBLIOGRAPHY            121
CHAPTER-10   
 ABBREVIATIONS            124
Mycophenolate Sodium Delayed-Release Tablets 360mg
------------------------------------------------------------------------------------------------------------
INTRODUCTION
The past two decades witnessed enormous research and development in the field of
medicine  and  pharmacy.  Research,  development  and  sales  of  drug  delivery  systems  are
increasing at  rapid pace throughout the world. This worldwide trend will intensify in this
decade as cuts in public health expenses demand lower costs and higher efficiency. To meet
this  demand,  many  efficient  drugs  currently  in  use  have  to  be  reformulated  within  the
delivery system that can be value-added for optimal molecular activity.
Now  a  significant  awareness  in  the  scenario  has  been  observed  that  instead  of
searching for new drugs using random hit or miss approach, the development of superior drug
delivery system which enhance the therapeutic efficacy of conventional drugs by controlling
the release rate or by targeting to the tissue site may be an effective approach to improve the
efficacy of the chemotherapeutic agent.
With many drugs, the basic goal of therapy is to achieve a steady-state blood or tissue
level that is therapeutically effective and non-toxic for an extended period of time. The design
of proper dosage regimen is an important element in accomplishing this goal1.
There are two ways to accomplish this goal,                   
1. Development  of  new,  better  and  safer  drugs  with
long half-lives and large therapeutic indices
2. Effective  and  safer  use  of  existing  drugs  through
concepts and techniques of controlled and targeted delivery systems2
1
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PRINCIPLES OF DOSAGE FORM DESIGN    
                                                    
Drugs  are  rarely administered  solely as  pure  chemical  substances,  but  are  almost
given as formulated preparations. The principal objective of dosage form design is to achieve
a predictable therapeutic response to a drug included in the formulation3.
Before a drug substance can be successfully formulated into a dosage form, many
factors must be considered. These factors can be broadly grouped in to 3 categories, 
1. Biopharmaceutical considerations (Factors affecting absorption of drugs)
2. Drug related factors (Physical and Chemical properties of the drug)
3. Therapeutic considerations (Disease to be treated and Patient factors)
Among various orally administered dosage forms (tablets, capsules, syrup, solution
etc…), the tablet dosage form is the most widely used. Compressed tablets are defined as
solid unit  dosage forms made by compaction of  the formulation containing the drug and
certain  fillers  or  excipients  selected  to  aid  in  the  processing  and  properties  of  the  drug
product.
Advantages of Tablets:        
The primary potential advantages of tablets4 are 
 They are the unit  dosage  forms,  which  offer  the great  capabilities  of  all  oral
dosage forms for the greatest dose precision and the least content variability.
 The cost is lowest of all oral dosage forms.
 They are the lightest and most compact of all.
2
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 They are in general the easiest and cheapest to packaging and shipment.
 Product  identification  is  potentially  the  simplest  and  cheapest,  requiring  no
additional  processing  steps  when  employing  an  embossed  or  monogrammed
punch face.
 They may provide the greatest ease of swallowing with the least  tendency for
hang  up  above  the  stomach,  especially  when  coated,  provided  the  tablet
disintegration is not excessively rapid.
 They lend themselves to certain special release profile products, such as enteric or
delayed release products.
 They are better suited to large scale production than with other unit oral dosage
forms.
 They  have  the  best  combined  properties  of  chemical,  mechanical  and
microbiological stability of all the oral forms. 
Disadvantages:
 Inspite  of  all  these  advantages,  tablets  also  possess  some  disadvantages4.  The
disadvantages of tablets include the following
 Some drugs resist compression into dense compacts, owing to their amorphous
nature or flocculent, low density character.
 Drugs with poor wetting properties, slow dissolution properties, intermediate to
large dosages, optimum absorption high in the GIT or any combination of these
features may be difficult or impossible to formulate and manufacture as a tablet
that will still provide adequate or full drug bioavailability.
3
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 Bitter  tasting  drugs,  drug  with  obnoxious  odor  or  drugs  that  are  sensitive  to
oxygen or atmospheric moisture may require encapsulation / entrapment prior to
compression / coating. 
CLASSIFICATION OF TABLETS
Tablets are classified in different ways5. They are
           a) Classification based on mode of administration 
1) Tablets to be swallowed
2) Chewable tablets
3) Tablets used in oral cavity
a. Buccal tablets
b. Sublingual tablets
b. Troches and lozenges
c. Dental cones
4) Tablets administered other than oral route
a. Implants
b. Vaginal tablets / suppositories
     b) Classification based on drug manufacturing process
       1) Standard compressed tablets
         2) Multiple compressed tablets
a. Compression – coated tablets
b.  Layered tablets 
        3) Coated tablets
     4) Molded tablets (Tablet triturates)
c) Classification based on drug release profile
 1) Fast Dissolving tablets
4
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 2) Immediate Release tablets
 3) Controlled Release tablets (Sustained Release tablets)
    4) Delayed Release tablets (Enteric coated tablets)
d) Tablets used to prepare solutions
1) Effervescent tablets
2) Dispersible tablets 
TABLET EXCIPIENTS:
The excipients are classified according to the function, they perform in the tablet4.     
They include the following.
a) Fillers / Diluents
b) Binders
c) Disintegrants
d) Lubricants
e) Glidant
f) Anti-adherents / anti-adhesives
5
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S.No CATEGOR
Y
DEFINITION EXAMPLES
1 Fillers / 
Diluents
They are the bulking agents 
which are inert substances 
added to active ingredient in 
sufficient quantity to make a 
reasonably sized tablet.
Lactose, Sucrose, Dextrose, 
Mannitol, Sorbitol, Starch, 
Micro crystalline Cellulose, 
Calcium carbonate, Calcium 
phosphate (dibasic and tribasic).
2 Lubricants These agents are required to 
prevent adherence of the 
granules to the punch or dies.
Metal stearates (0.5 to 2% of Ca,
Mg, Zn), Stearic acid fine 
powder (1 to 3%), Talc and 
Starch 1500 (5 to 10%), PEG 
4000 and 6000 (2 to 5%)
S.No CATEGOR
Y
DEFINITION EXAMPLES
3 Binders These are glue that holds the 
powder together to form 
granules. They are adhesives 
added to tablet formulation to 
provide cohesiveness required 
for bonding together granules, 
under compaction to form 
tablets.
Gelatin, Glucose, 
Methylcellulose, Water, Acacia, 
Starch paste, Alcohol, 
Polyvinylpyrrolidone, Sorbitol.
4 Disintegrants These agents are added to tablet
formulation / granulation for 
the purpose of causing the 
compressed tablet to break 
apart (disintegrate) when 
placed in aqueous environment.
Starch USP (5 to 20%w/w), 
Starch 1500(5 to15%w/w),
Avicel pH 101,102 
(Microcrystalline cellulose 5 to 
15%w/w), Sodium starch 
glycollate (Explotab 2 to 8% 
w/w), PVP and cross linked PVP
(0.5 to 10%w/w), Sodium 
Carboxyl Methyl cellulose.
5 Glidants These are materials that 
improve the flow 
characteristics of granulations 
by reducing inter particulate 
Aerosil ( Colloidal Silicon 
dioxide) (0.1 to0.5%w/w),
Talc (1 to 5%w/w) and Syloid.
6
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friction. 
TABLET MANUFACTURING PROCESS:
An outline of the various steps involved in the manufacturing of tablets6 by different
methods is mentioned below,
Wet Granulation Dry Granulation Direct Compression
 Milling  of  drugs  and
excipients
Milling of drugs and excipients
Milling  of  drugs  and
excipients
Mixing of milled products Mixing of milled products
Mixing  of  milled
products
Preparation  of  the  binder
solution
Compression  in  to  large  hard
tablets called slugs
Tablet compression
Mixing binder solution with
powder mixture to form wet
mass
Screening of slugs
Coarse  screening  of  wet
mass 
Mixing  with  lubricant  and
disintegrating agent
Drying moist granules Tablet compression
Screening dry granules with
lubricant and disintegrant
Mixing  Screened  granules
with  lubricant  and
disintegrant
Tablet compression
         
  The various process involved in the manufacturing of tablet are,
 Mixing
7
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 Granulation
 Drying
 Milling  / Sizing
 Compression
 Coating
 Packing
Mixing:
Mixing is defined as to put together (substances / things / one substance / thing with
another) in one mass assemblage with more or less through diffusion of the constituent
elements among one another. The three main mechanisms involved in mixing are diffusion,
convection and shear.
Types of mixers:
a)  Batch type:
Double cone blender, V- Shaped, Barrel, Planetary, Ribbon, and Fluid bed Granulator,
Fluidized bed dryer. 
b) Continuous:
Zig zag mixer.
Granulation: 
8
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Granulation is any process of size enlargement whereby small particles are gathered
together into large permanent aggregates to render them in to free flowing state.
Reasons for granulation:
 Render the material free flowing
 Densify material
 Prepare uniform mixtures that do not  separate
 Improve compression characteristics of drug
 Control the rate of drug release
 Removes dust
 Improve appearance of the tablet
Types of granulation:
 Wet Granulation.
 Dry Granulation.
 Direct Compression.
Wet Granulation – Schematic Representation:
Drug → Grind → Adjuvant → Blend → Binder Addition → Agglomerate → Pellets 
        
          Tablet¯  Compress ¬  Lubricate ¬  Blend ¬  Screen ¬  Dry
The  equipment  widely  used  for  wet  granulation  process  is  “RAPID  MIXER
GRANULATOR”.
Dry Granulation – Schematic Representation:
9
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Drug → Grind → Adjuvant → Blend → Pellet [Compaction] → Crush → Screen 
    ¬
           Tablet  ¯  Compress ¬  Lubricate ¬  Blend
Direct Compression Schematic Representation:
Drug → Grind → Adjuvants → Blend → Compress → Tablet
Drying:
Drying is defined as removal of water / other liquid from a solid / semisolid mass by
evaporative process.
The various equipments used for drying are 
 Tray Dryer
  Turbo tray dryer
 Fluidized Bed Dryer
 Spray Dryer
Compression:
Compression  is  defined  as  a  process  of  applying  pressure  to  a  material.  In
Pharmaceutical tabletting an appropriate volume of granules in to die cavity is compressed
between upper punch and lower punch to consolidate the material into a single solid matrix,
which is subsequently ejected from the die cavity as “INTACT TABLET”
The equipments used for compression are 
10
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• Single Punch Tablet Compression Machine
• Rotary Tablet Compression Machine.
THE SUSTAINED RELEASE CONCEPT
Sustained  release,  sustained  action,  prolonged  action,  controlled  release,  extended
action are the terms used to identify drug delivery systems that are designed to achieve a
prolong therapeutic effect by continuously releasing medication over an extended period of
time after administration of single dose. The extended, slow release of controlled release drug
products produces a relatively flat, sustained plasma drug concentration that avoids toxicity
(from high drug concentrations) or lack of efficacy (from low drug concentrations)7.
The desirable therapeutic advantages of a sustained release form are,
1. Frequency of drug administration is reduced and thus patient compliance can
be improved.         
2. The  blood  level  oscillation  characteristics  of  multiple
dosing of conventional dosage forms is reduced.
3. Total  amount  of  drug  administered  can  be  reduced,  thus  maximizing
availability within minimum dose.
4. Safety margin of high potency drugs can be increased, and the incidence of
both local and systemic adverse effects can be reduced. 
5. Overall, administration of sustained release forms enables
increased reliability of therapy1b.
11
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There are various approaches in delivering a therapeutic substance to the target site in
a  sustained  release  fashion.  Microspheres,  which  are  matrix  systems  containing  drug
throughout (either in solution or microcrystalline form) the structure are potential candidates
for oral sustained release 8.
Typical plasma drug concentration versus time profiles for an ideal sustained
release microencapsulated product (A) and conventional dosage form (B) repeatedly given
orally9. 
Probably the earliest work in the area of sustained drug delivery dosage forms can be traced
to the  1938 patent  of  Israel  Lipowski.   This work involved  coated pellets  for  prolonged
release of a drug and was presumably the forerunner to the development of the coated particle
approach 10.
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With many drugs, the basic goal of therapy is to achieve a steady state blood on tissue
level that is therapeutically effective and nontoxic for an extended period of time.  The design
of  proper  dosage  regimen  is  an  important  element  in  accomplishing  this  goal.   A basic
objective in dosage form design is to optimize the delivery of medication so as to achieve a
measure of control of the therapeutic effect in the face of uncertain fluctuations in the In-vivo
environment in which drug release takes place 11. 
Sustained  release,  sustained  action,  prolonged  action,  controlled  release,  extended
action, timed release are terms to identify drug delivery systems that are designed to achieve
a prolonged therapeutic effect by continuously releasing medication over and extended period
of time after administration of a single dose.  
Oral injection has long been the most convenient and commonly employed route of
drug delivery.  Indeed, for sustained release of systems the oral route of administration has
received the most attention with respect to research on physiological and drug constraints as
well as design and testing of products.  This is because there is more flexibility in dosage
form design for the oral route than there is for the parenteral route12.
13
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MODIFIED RELEASE SYSTEMS
To overcome the potential problems associated with conventional drug therapy modified
release systems were developed and may be divided into four categories 13.
1. Sustained release
a. Controlled release
b. Prolonged release
2. Site specific release
3. Receptor 
4. Delayed release
Sustained release system
Sustained  release  are  that  which  achieves  slow release  of  drug  over  an  extended
period of time and in this drug is initially made available to the body in amount to cause the
desired pharmacological response.
Controlled release system
An  ideal  controlled  drug  delivery  system  is  that  which  delivers  the  drug  at
predetermined  rate,  locally  or  systemically  for  the  predetermined  period  of  time.   Thus
maintaining constant drug level in blood or target tissue. 
Site specific and receptor release system
Site specific and receptor release and targeted release system refers to targeting of the
drug directly to a certain biological location.
14
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Prolonged release system
Prolonged  release  system,  prolongs  the  duration  of  action  without  maintaining  a
constant drug blood level.
Conventional dosage forms are associated with many side effects such as the initial
dose may not be adequate enough to reach the therapeutic range to elicit pharmacological
response.  Besides this the repeated drug administration at the equal intervals may result in
severe  side  effects.   These  problems  of  conventional  dosage  forms  are  overcome  by
controlled drug delivery systems since sustained release dosage forms usually consists of two
parts an immediately available dose to establish the blood level quickly and a sustaining part
that contains several times the therapeutic dose for protracted drug levels 
In conventional drug therapy it can be seen from the figure that the administration of
drug by either intravenous injection or an extravascular route e.g. orally, intramuscularly or
rectally does  not  maintain drug blood level  within the therapeutic  range for  an extended
period of time.  The short  action is  due to the inability of conventional  dosage forms to
control temporal delivery 13. 
15
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FIGURE – 1
Drug Blood Level Vs Time Profile for Intravenous injections (eg. Dextrose and Sodium
Chloride Injections) and extra vascular route of administration (Acetaminophen tablet
given orally) 
Oral drug delivery has been known for decades as the most widely utilized route of
administration among all  the routes  that  have been explored for  the systemic delivery or
drugs via various pharmaceutical products of different dosage forms.  The reasons that the
oral route achieved such popularity may be in part attributed to its case of administration as
well as the traditional belief that by oral administration the drug it as well absorbed as the
foodstuffs that are ingested daily. In fact, the development of a pharmaceutical product for
oral  delivery,  irrespective  of  its  physical  form (solid,  semisolid,  or  liquid  dosage  form),
involves varying extents of optimization of dosage form characteristics within the inherent
constraints of gastrointestinal (GI) physiology 14. 
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Pharmaceutical  products  designed for  oral  delivery and  currently available on the
prescription and over-the counter markets are mostly the immediate-release type, which are
designed  for  immediate  release  of  drug  for  rapid  absorption.   Because  of  their  clinical
advantages  over  immediate-release  pharmaceutical  products  containing  the  same  drugs,
sustained-release pharmaceutical products, such as those formulated on the basis of spansule
coating  technology,  have  over  their  introduction  into  the  marketplace.   Recently,  a  new
generation of pharmaceutical products, called controlled-release drug delivery systems, such
as those developed form the osmotic pressure-activated drug delivery system, have recently
received regulatory approval for marketing and their pharmaceutical superiority and clinical
benefits over the sustained-release and immediate-release pharmaceutical products have been
increasingly recognized.
All the pharmaceutical products formulated for systemic delivery via the oral route of
administration.   Irrespective  of  the  mode of  delivery immediate,  sustained  or  controlled
release and the design of dosage forms (either solid dispersion or liquid) must be developed
within the intrinsic characteristics of GI physiology.  Therefore, a fundamental understanding
of various  disciplines  including GI physiology,  pharmacokinetics,  pharmacodynamics  and
formulation  design  is  essential  to  achieve  a  systematic  approach  to  the  successful
development of an oral pharmaceutical dosage form (or drug delivery system).  The more
sophisticated a delivery system the greater  is  the complexity of  these  various  disciplines
involved in the design and optimization of the system.  In any, case the scientific frame work
required for the successful development of an oral drug delivery system consists of a basic
understanding  of  the  following  three  aspects:  (i)  physicochemical,  pharmacokinetic  and
pharmacodynamics  characteristics  of  the  drug,  ii.  the  anatomic  and  physiologic
17
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characteristics of the gastrointestinal tract and iii. physicomechanical characteristics and the
drug delivery mode of the dosage form to be designed.   
Although it is often impractical to alter the physicochemical, pharmacokinetic and  or
pharmacodynamics characteristics of a drug to be delivered by a chemical approach, such as
the synthesis of an analog or medically undesirable to modify the anatomic and physiologic
characteristics of the gastrointestinal tract, the design of a controlled-release oral dosage form
by optimization of dosage form characteristics with GI anatomy and physiology taken into
consideration could provide some opportunity to rationalize the systemic delivery of drugs
and maximize their therapeutic benefits.
The term “Controlled-release oral dosage form: is not new to most people working in
various fields of pharmaceutical research and development. In fact, approximately 30 years
ago, the U.S.  Food and Drug Administration (FDA) published regulatory requirements for
controlled-release  products.   Unfortunately  there  has  been  a  proliferation  of  controlled-
release  dosage  forms  on  the  marketplace  that  may  have  little  rationale  and  provide  no
advantages over the same drugs in conventional dosage forms. Over the last decades there
has also been an increase in the use of controlled-release labeling claim.
18
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Potential Advantages of Sustained Drug Therapy
Sustained drug therapy is used for the following purposes 11
1. Patient compliance due to reduction in frequency of dosing
2. Employ minimum drug
a. Minimize or eliminates local and systemic side effects.
b. Obtain less potentiating or reduction in drug activity with chronic use.
c. Minimize drug accumulation with chronic dosing.
3. Improve efficacy in treatment 
a. Cure or  control condition more promptly
b. Improve control of condition.
19
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DELAYED RELEASE SYSTEM17
Delayed release systems are those that used repetitive intermittent dosing of the drug
from one or more immediate release units incorporated into single dosage form.
Definition:
Delayed-Release tablets that are intended to resist the gastric fluid and to release their
active substance in the in the intestinal fluid. Usually they are prepared from granules or
particles already covered with a gastro-resistant coating or in certain cases by covering tablets
with a gastro-resistant Enteric coated tablets.
      
20
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For tablets covered with a gastro-resistant coating carry out the test for disintegration 
with the following modifications. Use 0.1M Hydrochloric Acid as a liquid. Operate the 
apparatus for 2 hours, without the discs and examine the state of the tablets. The time of 
resistance to the acid medium varies according to the formulation of the tablets to be 
examined. An authorized deviation is not less than 2 hours. No tablet shows signs of either 
disintegration or cracks that would allow to escape of the contents. Replace the acid by 
phosphate buffer solution PH 6.8 and add a disc to each tube. Operate the apparatus for 60 
minutes and examine the state of the tablets. If the tablets comply because of adherence to the
discs, repeat the test a further 6 tablets omitting the discs. The tablets comply with the test if 
all 6 have disintegrated.
ENTERIC COATING TECHNIQUE:
This  technique  is  used  to  protect  the  tablet  core  from  disintegration  in  the  acid
environment of the stomach for one or more of the following reasons:
 Prevention of acid attack on active constituents unstable at low pH;
 To protect the stomach from the irritant effect of certain drugs;
 To facilitate absorption of a drug that is preferentially absorbed distal to the stomach.
The following polymers are among those commonly used for the purposes of enteric coating:
 Cellulose acetate phthalate
 Polyvinyl acetate phthalate
 Suitable acrylic derivatives.
21
------------------------------------------------------------------------------------------------------------
Formulation Development and Evaluation
Mycophenolate Sodium Delayed-Release Tablets 360mg
------------------------------------------------------------------------------------------------------------
Because they possess free carboxylic acid groups on the polymer backbone, they exhibit a
differential pH solubility profile. They are almost insoluble in aqueous media at low pH, but as
the pH rises they experience a sharp, well denned increase in solubility at a specific pH, e.g.
pH 5.2 for cellulose acetate phthalate.
COMPARISON CHART FOR DELAYED-RELEASE WITH IMMIDIATE RELEASE
DOSAGE FORM
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REVIEW OF LITERATURE
 M Salvadori, H Holzer, A Mattos18 The introduction of mycophenolate mofetil 
represented a major advance in transplant medicine, although optimal use may be 
limited by gastrointestinal side-effects. An enteric-coated formulation of 
mycophenolate sodium (myfortic®) has been developed with the aim of improving the 
upper GI tolerability of mycophenolic acid. Therapeutic equivalence of EC-MPS (720
mg b.i.d.) and MMF (1000 mg MMF b.i.d.).
 Staatz, Christine E, Tett, Susan E19 This review aims to provide an extensive 
overview of the literature on the clinical pharmacokinetics of mycophenolate in solid 
organ transplantation and a briefer summary of current pharmacodynamic 
information. Strategies are suggested for further optimisation of mycophenolate 
therapy and areas where additional research is warranted are highlighted. 
Mycophenolate has gained widespread acceptance as the antimetabolite 
immunosuppressant of choice in organ transplant regimens. Mycophenolic acid 
(MPA) is the active drug moiety.
 L Chan, S Mulgaonkar, R Walker20 Patient-Reported Gastrointestinal symptom 
burden and health-related quality of  Life following Conversion from Mycophenolate 
Mofetil to Enteric-Coated Mycophenolate Sodium.
 Klemens Budde, Petra Glander, Lutz Fritsche, Duska Dragun21 Enteric-coated 
mycophenolate sodium (myfortic®, Novartis Pharma AG) is an advanced formulation 
delivering mycophenolic acid . Enteric-coated mycophenolate sodium was designed 
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to improve mycophenolic acid -related upper gastrointestinal adverse events by 
delaying the release of mycophenolic acid until reaching the small intestine.
 K Budde, P Glander, BK Kramer, W Fischer22 Conversion From Mycophenolate 
Mofetil to Enteric-Coated Mycophenolate Sodium in Maintenance Renal Transplant 
Recipients Receiving Tacrolimus. Clinical, Pharmacokinetic and Pharmacodynamic 
activity.
 G Crotts, A Sheth, J Twist, I Ghebre-Sellassie23 Development of an enteric coating 
formulation and process for tablets primarily composed of a highly water-soluble, 
organic acidic tablet core should be applied to prevent retardation in drug release.
 Ciancio G, Sageshima J, Burke GW, Rosen A, Miller J24 A Randomized Trial 
Comparing Tacrolimus/ Mycophenolate Mofetil (CellCept) Versus 
Tacrolimus/Enteric-Coated Mycophenolate Sodium (Myfortic) In First Renal 
Transplants Induced With Both Daclizumab And Thymoglobulin. With Steroid 
Avoidance.
 Oellerich, Michael; Shipkova, Maria; Schütz, Ekkehard; Wieland, 
Eberhard25Pharmacokinetic and Metabolic Investigations of Mycophenolic Acid in 
Pediatric Patients After Renal Transplantation: Implications for Therapeutic Drug 
Monitoring.
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 W.Arns26 Noninfectious Gastrointestinal  Complications of Mycophenolic Acid 
Therapy. Mycophenolic acid , a reversible inhibitor of inosine 5″-monophosphate 
dehydrogenase (IMPDH), selectively inhibits T- and B-cell proliferation. 
Mycophenolic acid exposure correlates inversely with the risk of acute rejection. 
Mycophenolate mofetil  is an immediate-release formulation of  Mycophenolic Acid 
that is absorbed in the stomach and small intestine.
 Theodore W. Perry, Uwe Christians, James F. Trotter, Jamie Bendrick-Peart27 
Mycophenolate mofetil is one of the major immunosuppressive agents used in liver 
transplantation recipients. In an attempt to mitigate one of the most common side 
effects of Mycophenolate mofetil (gastrointestinal symptoms), enteric-coated 
mycophenolate sodium was developed. In this study, we report the pharmacokinetic 
profile of enteric-coated mycophenolate sodium in stable liver transplantation 
recipients administered a single 720 mg dose.
 Kobashigawa JA, Relund DG, Gerosa G, Almenar L, Livi U, Ross H Yonan N28 
Similar Efficacy and Safety of Enteric-coated Mycophenolate Sodium  Compared 
with Mycophenolate Mofetil  in De Novo Heart Transplant Recipients: Results of a 
12-Month, Single-blind,  Randomized, Parallel-group, Multicenter Study.
 Arns WW, Glander P, Schuhmann R,  Mai I, Fischer WH, Budde K29 
Conversion From Tacrolimus to Everolimus Does not Influence The 
Pharmacokinetic. But Increases Pharmacodynamic Response Of Mycophenolate 
Sodium In Renal Transplant Patients.
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 Massari P, Duro-Garcia V, Girón F, Hernández E, Juárez F, Castro C, Toledo 
M30 Safety assessment of the conversion from mycophenolate  mofetil to 
mycophenolate sodium in stable renal transplant recipients. Full dose tolerability 
with enteric coated mycophenolate sodium.
 Dumortier J, Gagnieu M-C, Salandre J, Guillem P, Adham M, Boillet O31 
Conversion from Mycopenolate mofetil to enteric-coated Mycopenolate sodium in 
liver transplant patients presenting gastrointestinal disorders.
 Bjarnason I.32 Enteric coating of mycophenolate sodium: a rational approach to 
limit topical gastrointestinal lesions and extend the therapeutic index of 
mycophenolate. 
 Fanak et al., (2012)33 reported that physical and chemical stability of Mycophenolate 
Mofetil (MMF) suspension prepared at the hospital. Suspension formulations were 
prepared from both tablets and capsules forms of MMF. Thereafter the stability 
parameters such as pH, microbial control, thermal and physical stability and particle 
sizes were evaluated. The amount of MMF, in the suspension was measured at various
time points by HPLC. According to the obtained results in this study, capsule-based 
suspension was stable for as long as 14 days at 5°C.
 Kathleen et al., (2012)34 reported that race and drug formulation influence on 
Mycophenolic acid pharmacokinetics in stable renal transplant recipients. The Journal
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of Clinical Pharmacology. Mycophenolic acid clearance and dose-normalized area 
under the concentration-time curve 0-12 (AUC) were determined. Mixed model 
statistics evaluated the main effects of race, drug formulation, and interaction of race 
and drug formulation (R × D) with albumin, cyclosporine trough, renal function, and 
diabetes and enterhepatic recirculation. The findings concluded that race influences 
MPA exposure between MMF and EC-MPS and may warrant therapeutic monitoring 
during formulation conversion.
 Hari and Karen et al., (2012) 35 reported that current state of renal transplant 
immunosuppression: Present and future. World Journal of Transplant 2012; 2(4): 51-
68. Regimens designed to limit or eliminate calcineurin inhibitors and/or 
corticosteroid use are actively being pursued. An ideal immunosuppressive regimen 
limits toxicity and prolongs the functional life of the graft. This article contains a 
critical analysis of clinical data on currently available immunosuppressive strategies 
and an overview of therapeutic moieties in development.
 Zeher, et al., (2011)36 reported that efficacy and safety of enteric-coated 
Mycophenolate sodium in combination with two glucocorticoid regimens for the 
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treatment of active lupus nephritis. This exploratory study suggests that EC-MPS may
facilitate glucocorticoid reduction without loss of efficacy in patients with active 
lupus nephritis, but results require confirmation in a controlled, longer-term study 
versus the current standard of care.
 Esquivel et al., (2010) 37 reported that comparison of dissolution properties of 2 
enteric-coated formulations containing Mycophenolate sodium: Myfortic vs Femulan.
For both formulations, mycophenolate sodium content was within the 90% to 110% 
range of the label claimed dose, and no impurities were present as determined at high-
performance liquid chromatography. Mycophenolate sodium release was assayed by 
applying the US Pharmacopeia apparatus 2 dissolution test at 2 different pH values 
(1.2 and 6.8) to mimic conditions in the stomach and the small intestine, respectively. 
At pH 1.2, mycophenolate sodium release was less than 2%, with respect to the label 
claimed dose, for both formulations. At pH 6.8, mean (range) mycophenolate sodium 
release with Myfortic was 104.9% (104.0%–105.6%), and with femulan was 62.3% 
(51.3%–67.7%); the difference between formulations achieved statistical significance 
28
------------------------------------------------------------------------------------------------------------
Formulation Development and Evaluation
Mycophenolate Sodium Delayed-Release Tablets 360mg
------------------------------------------------------------------------------------------------------------
 Sarah et al., (2010) 38 reported that therapeutic drug monitoring of mycophenolate 
mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus 
erythematosus. MPA AUC between 0 and 12 h (AUC0–12h), Cmax, Tmax, and 12-h trough 
concentrations (C12h) were determined. Means of dose-normalized MMF– or EC-
MPS–MPA Cmax were 64.6 ± 25 and 61.4 ± 27.1 h mg/l, respectively. MPA Tmax for 
EC-MPS was longer and more variable than for MMF. MMF-MPA AUC0–12h and C12h 
were correlated (r = 0.78, p = 0.0001), but EC-MPS–MPA Cmax and single 
concentrations were weakly correlated. A limited-sampling strategy (LSS) combining 
Cmax and C12h gave satisfactory predictive performance to estimate MPA AUC0–12h after
EC-MPS administration.
 Dario et al., (2007) 39 reported that Pharmacokinetics of Mycophenolate sodium and 
comparison with the Mofetil formulation in stable kidney transplant recipients. 
Patients who were taking the enteric-coated formulation had mycophenolic acid time 
of occurrence for maximum drug concentration that ranged from 0 to 480 min and 
higher dosage-adjusted mycophenolic acid trough levels compared with patients who 
were given mycophenolate mofetil. Conversion from the enteric-coated formulation 
of mycophenolate sodium to mycophenolate mofetil resulted in an improvement of 
the mycophenolic acid kinetics profiles.
 Budde et al., (2004) 40 reported that enteric-coated Mycophenolate sodium: safe 
conversion from mycophenolate mofetil in maintenance renal transplant recipients. 
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Enteric-coated mycophenolate sodium (EC-MPS) is an advanced formulation 
delivering mycophenolic acid (MPA), developed with the objective of improving 
MPA-related upper GI adverse events. A pivotal, 12-month, phase III, randomized, 
multicenter, double-blind, double-dummy, parallel group study investigated whether 
stable renal transplant patients can be converted from MMF to EC-MPS therapy 
without compromising tolerability or efficacy.
 Maurizio et al., (2004) 41 reported that enteric-coated mycophenolate sodium is 
therapeutically equivalent to mycophenolate mofetil in de novo renal transplant 
patients. An enteric-coated formulation of mycophenolate sodium (EC-MPS; 
myfortic) has been developed with the aim of improving the upper GI tolerability of 
mycophenolic acid. Within 12 months, 15.0% of EC-MPS patients and 19.5% of 
MMF patients required dose changes for GI adverse events (p=ns). Enteric-coated-
MPS 720 mg b.i.d. is therapeutically equivalent to MMF 1000 mg b.i.d. with a 
comparable safety profile.
 Monica et al., (2004) 42 reported that Mycophenolate sodium versus Mycophenolate 
mofetil: A review of their comparative features. From the findings, this study 
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concludes that considering the limited number of studies comparing these two agents, 
it is difficult to establish significant concluding remarks of the advantages of using 
ECMS over MMF. What is obvious, however, is that ECMS does represent an 
alternative to the significant number of patients suffering from the common 
gastrointestinal intolerance reported with MMF. Whether ECMS's consistent capacity 
to achieve the target AUC (0-24) of >30 µg/ml is of clinical relevance needs further 
investigation.
 Nashan et al., (2004) 43 reported that conversion from mycophenolate mofetil to 
enteric-coated mycophenolate sodium in maintenance renal transplant patients: 
Preliminary results from the myfortic prospective multicenter study. Enteric-coated 
mycophenolate sodium (EC-MPS) is a new formulation delivering mycophenolic acid
developed with the aim of improving upper GI tolerability. A large prospective, open-
label, multicenter program (myPROMS: myfortic PROspective Multicenter Study) is 
underway to determine the efficacy and safety of EC-MPS, in combination with 
cyclosporine microemulsion in a large population of de novo and maintenance renal 
transplant recipients. The preliminary data summarized here are from two 
subprotocols, which investigated the benefits of converting maintenance renal 
transplant patients receiving MMF to EC-MPS. The 3-month interim analyses suggest
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that the conversion from MMF to EC-MPS is well tolerated in maintenance renal 
transplant recipients.
 Budde et al., (2003) 44 reported that enteric-coated Mycophenolate sodium can be 
safely administered in maintenance renal transplants patients from the results of a 1 –
year study. American Journal of Transplantation 2003; 4: 237-243. The study 
concluded that renal maintenance patients can be converted from MMF to EC-MPS 
without compromising the safety and efficacy profile associated with MMF.
 William et al., (2003) 45 reported that immunosuppression with Mycophenolic Acid: 
One size does not fit all. An enteric-coated formulation of mycophenolate sodium 
(Myfortic) is in the final stages of drug development. Presumably the enteric coating 
avoids upper GI tract toxicity and delivers the drug more distally, where it may be 
absorbed better. Randomized blinded trials are in progress, but thus far there is no 
evidence that this formulation has a better efficacy or side effect profile than MMF.
 Schuurman et al., (2002) 46 reported that Mycophenolate sodium: tolerability and 
efficacy in transplantation in the rat. Mycophenolate sodium (MPS) is in clinical 
development as an enteric-coated formulation to alleviate this gastrointestinal adverse 
effect. Accompanying this development, MPS and MMF were evaluated in a 
tolerability study in rats and in efficacy studies in rat allo- and xenotransplantation 
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models. The minimal effective dose to prevent rejection of a kidney or heart allograft 
or a hamster heart xenograft is a daily dose of 10-20 mg/kg MPS, at which dose the 
first adverse side effects can be observed: the compound at 40 mg/kg is not tolerated. 
This window is even narrower for MMF than for MPS, and in most models, a 
minimal effective MMF dose could not be established. The window between optimal 
immunosuppression and adverse side effects is larger when the compounds are given 
in combination with cyclosporine A: in all models investigated combinations were 
established yielding long-term survival without histologic signs of rejection and 
without signs of side effects. Thus, the combination of an IMPDH inhibitor (MPS, 
MMF) and a calcineurin inhibitor (cyclosporine A) enables fine-tuning in achieving 
optimal immunosuppression avoiding drug side effects.
AIM
The aim of formulation development was to formulate Mycophenolate sodium Tablets
360mg (Enteric coated), which are robust, stable and bio-equivalent to the Generic product of
Myfortic  360mg  Tablets  marketed  by  Novartis  pharma  stein  AG which  is  used  as
Reference Listed Product for comparison & Developmental  studies.  Product  development
was carried out on Mycophenolate sodium Tablets 360mg. All the critical process parameters
identified at development stage were confirmed and proved that the process is capable of
producing  a  drug  product  of  the  required  quality  with  the  proposed  process  &  product
parameters.
OBJECTIVE
The objective of the present study is to:
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 To develop a formulation of Delayed-Release tablets of Mycophenolic acid of 
strength 360mg which shall be bioequivalent to Reference product.
 To develop a best processing method using different grades of excipients.
 To develop a seal coating and enteric coating formula by various weight buildup.
 To develop and evaluate the in-vitro dissolution release of the prepared tablets and to 
compare with the Reference product.
 Data characterization and compilation of the final formulated product.
PLAN OF WORK
 Literature survey
 Reference product evaluation
 Pre-formulation Studies
 Drug-Excipients Compatibility Studies – For selection of compatible excipients.
 Formulation development for core tablet.
 Formulation development for seal coating.
 Formulation development for enteric coating.
 Formulation development for dissolution comparable with Innovator product.
 Stability studies of finalized product
Physical and chemical evaluation of test product
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 Weight variation
 Thickness
 Hardness 
 Friability
 Disintegration
 Dissolution
 Related Substances
DRUG PROFILE
DESCRIPTION AND COMPOSITION OF THE DRUG PRODUCT
             Each Enteric coated Tablet contains: 
                   Mycophenolic acid …… 360mg.
FORMULATION STUDIES
Mycophenolate sodium Tablet  is  indicated as  an  immunosuppressant drug used to
prevent  rejection in  organ  transplantation.  It  was  initially  marketed  as  the  prodrug
mycophenolate  mofetil (MMF)  to  improve  oral  bioavailability.  More  recently,  the  salt
mycophenolate sodium has also been introduced. 
MANUFACTURER FOR ACTIVE SUBSTANCE
The active substance has been procured from Biocon Ltd. India/Concord Ltd India.
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COMPONENTS OF DRUG PRODUCTS:
Physico-Chemical characterization of  Mycophenolate sodium:
Mycophenolate sodium is an off white crystalline hygroscopic powder. It
is slightly soluble in methanol and very slightly soluble in water.
Molecular Formula:  C17H20O6
Molecular weight    :  320.34 g·mol−1
Chemical Structure:
PHARMACOLOGY15
Mycophenolate sodium (MPS) is an enteric coated, delayed release monosodium salt 
of Mycophenolate Acid (MPA). The active ingredient, MPA, was first discovered in 1896 as a
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------------------------------------------------------------------------------------------------------------
Formulation Development and Evaluation
Mycophenolate Sodium Delayed-Release Tablets 360mg
------------------------------------------------------------------------------------------------------------
fermentation product of several Penicillium species. While it was initially studied as an 
antibiotic, it was in the early 1970’s that MPA was demonstrated to suppress antibody 
responses and prolong skin-graft survival in mice. Inhibitors of inosine monophosphate 
dehydrogenase (IMPDH) are effective immunosuppressants and MPA is a potent, selective, 
uncompetitive and reversible inhibitor.
In vitro studies have demonstrated that only free MPA is available to inhibit IMPDH 
after NADH (nicotinamide adenine dinucleotide) is released but before XMP which is the 
committed step in de novo guanosine nucleotide synthesis. The structure of IMPDH also 
indicates that MPA inhibits the enzyme by simultaneously mimicking the nicotinamide 
portion of the NAD cofactor and a catalytic water molecule. Clinical studies have shown 
MPA to be 4.8 times more active against type-II IMPDH than type-I, thereby increasing its 
selectivity toward activated lymphocytes. Enteric-coated MPS was developed for the 
potential to reduce MPA-associated side effects such as nausea, vomiting, dyspepsia, 
abdominal pain and discomfort based on the hypothesis of sharing a similar mechanism of GI
toxicity with that of non-steroidal anti-inflammatory agents (NSAIDs). Preliminary studies 
showed that MPA is a potent uncoupler of mitochondrial oxidative phosphorylation similar to
NSAIDs. 
PHARMACOKINETICS15
 ABSORPTION
                   In vitro studies demonstrated that the enteric-coated mycophenolic acid 
tablet does not release mycophenolic acid under acidic conditions (pH less than 5) as in the 
stomach but is highly soluble in neutral pH conditions as in the intestine. Following 
mycophenolic acid oral administration without food in several pharmacokinetic studies 
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conducted in renal transplant patients, consistent with its enteric-coated formulation, the 
median delay (tlag) in the rise of mycophenolic acid concentration ranged between 0.25 and 
1.25 hours and the median time to maximum concentration (TMAX) of mycophenolic acid 
ranged between 1.5 and 2.75 hours. In comparison, following the administration of 
mycophenolate mofetil, the median TMAX ranged between 0.5 and 1 hour. In stable renal 
transplant patients on modified cyclosporine-based immunosuppression, GI absorption, and 
absolute bioavailability of mycophenolic acid following the administration of mycophenolic 
acid delayed-release tablet was 93% and 72%, respectively. Mycophenolic acid 
pharmacokinetics is dose proportional over the dose range of 360mg to 2,160mg. In the early 
post transplant period, mean mycophenolic acid AUC and CMAX were approximately one-half 
of those measured 6 months post transplant. The trials in other solid organ transplant types; 
heart and liver, have demonstrated equivalent pharmacokinetic parameters relative to MMF. 
There is significant intra and inter-patient variability in pharmacokinetic parameters which is 
dependent on organ type, concurrent immunosuppressive therapy and weeks post-transplant.
          DISTRIBUTION
          The mean (± SD) volume of distribution at steady state and elimination phase 
for MPA is 54 (± 25) L and 112 (± 48) L, respectively. MPA is highly protein bound to 
albumin, >98%. The protein binding of mycophenolic acid glucuronide (MPAG) is 82%. The 
free MPA concentration may increase under conditions of decreased protein binding (uremia, 
hepatic failure, and hypoalbuminemia).
METABOLISM
              MPA is metabolized principally by glucuronyl transferase to glucuronidated 
metabolites. The phenolic glucuronide of MPA, mycophenolic acid glucuronide (MPAG), is 
the predominant metabolite of MPA and does not manifest pharmacological activity. The acyl
glucuronide is a minor metabolite and has comparable pharmacological activity to MPA. In 
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stable renal transplant patients on cyclosporine, USP (MODIFIED) based 
immunosuppression, approximately 28% of the oral Myfortic dose was converted to MPAG 
by presystemic metabolism. The AUC ratio of MPA:MPAG:acyl glucuronide is 
approximately 1:24:0.28 at steady state. The mean clearance of MPA was 140 (± 30) mL/min.
ELIMINATION23
                   The majority of MPA dose administered is eliminated in the urine 
primarily as MPAG (>60%) and approximately 3% as unchanged MPA following MPS 
administration to stable renal transplant patients. The elimination half-life of MPA and MPAG
ranged between 8 and 16 hours, and 13 and 17 hours, respectively.
EFFECTS OF FOOD24
                      The effect of a high fat meal compared to the fasting state has been 
assessed. There was no effect on MPA AUC, along with a 33% decrease in CMAX and a 
significant delay in TMAX.26
DRUG INTERACTION
The following drug interaction studies have been conducted with Mycophenolate 
sodium 360mg enteric coated tablets.
 Gastroprotective agents: Antacids with magnesium and aluminum hydroxides
 Proton Pump inhibitors:
 Cholestyramine and Drugs that Bind Bile Acids:
 Oral Contraceptives: levonorgesterol
 Live Vaccines: Influenza vaccination
ADVERSE REACTION
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  The principal adverse reactions associated with the administration of Mycophenolate
sodium include constipation, nausea, and urinary tract infection in de novo patients and 
nausea, diarrhea and nasopharyngitis in maintenance patients.
THERAPEUTIC DRUG MONITORING23
                      Therapeutic drug monitoring in the context of MMF and MPS has been 
defined as a diagnostic method that assigns drug concentration values, based on studies 
relating patient outcome measurements to drug concentrations, to predict efficacy (usually a 
lowered rate of graft rejection) or toxicity (short-term or long-term) in individual patients.27 
Renal function and drug related side effects has been found for the 12hours dose interval 
MPA AUC0-12 and the pre-dose trough MPA concentration. Maximum plasma concentration 
(Cmax ) (>30mg/L) and AUC values (>microgram*h/ml) for MPA are associated with a 
lower risk of renal allograft rejection; while levels of therapeutic exposure >60-70 
microgram*h/ml are associated with a significant proportion of patients withdrawing from 
treatment due to adverse events, mainly GI intolerability.
DOSAGE AND ADMINISTRATION
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                  MPS is available in 180mg and 360mg enteric coated tablets.12 Because 
of this coating the tablets should not be crushed. The pharmacokinetic behavior of MPA and 
MPAG previously described in this document require that both MPS and MMF be 
administered twice daily. The dosage of MPS tablets was designed such that a 720mg dose of 
MPS would provide the nearest molar equivalent of MPA provided by 1000mg of MMF. The 
MMF daily dose of 1000mg BID is accepted based on the results of pivotal trials that have 
shown this to be the accepted dose for prophylaxis in renal transplantation.7 Daily doses of 
MPS 720mg and MMF 1000mg are utilized for liver transplant recipients while higher doses 
of MPS 2160mg and MMF 3000mg are used for heart transplant recipients.
EXCIPIENT PROFILE
Excipients are selected based on the excipients of Reference Product. Apart from the
Reference product excipients other excipients are selected based on the proposed composition
& possible use of them.
LACTOSE MONOHYDRATE
Nonproprietary Names
• BP: Lactose monohydrate 
• PhEur: monohydricum Lactosum
• JP: Lactose 
• USPNF: Lactose monohydrate
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Chemical Name 
O-β-d-Galactopyranosyl-(1→4)-α-d-glucopyranose monohydrate 
Empirical Formula 
C12H22O11·H2O  
Functional Category
Binding agent, diluents for dry-powder inhalers, tablet binder and diluents.
Applications in Pharmaceutical Formulation or Technology
Lactose is widely used as a filler or diluents in tablets.
Description
Lactose is white to off-white crystalline particles or powder, odorless and slightly 
sweet-tasting. In the solid state, lactose appears as various isomeric forms, the stable 
crystalline forms of lactose are α-lactose monohydrate, β-lactose anhydrous and stable α-
lactose anhydrous.
Stability and Storage Conditions
Mold growth and brown coloration may occur under humid conditions. Lactose 
should be stored in a well-closed container in a cool, dry place.
Incompatibilities
Lactose is also incompatible with amino acids, aminophylline, amphetamines and 
lisinopril. 
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Safety
Adverse reactions to lactose are largely lead to cramps, diarrhea, distension, and 
flatulence
POVIDONE 
Nonproprietary Names
• BP: Povidone
• JP: Povidone
• PhEur: Povidonum 
• USP: Povidone
Synonyms
poly [1-(2-oxo-1-pyrrolidinyl)ethylene]; polyvidone; polyvinylpyrrolidone; PVP; 1-vinyl-2-
pyrrolidinone polymer.
Chemical Name 
1-Ethenyl-2-pyrrolidinone homopolymer 
Empirical Formula 
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(C6H9NO) n 
Functional Category
Disintegrant, dissolution aid, suspending agent and tablet binder.
Applications in Pharmaceutical Formulation or Technology
In tableting, Povidone is used as binders in wet-granulation processes and as coating 
agents.
Description
Povidone occurs as a fine, white to creamy-white colored, odorless or almost 
odorless, hygroscopic powder and freely soluble in acids, chloroform, methanol, and water 
practically insoluble in ether, hydrocarbons and mineral oil.
Stability and Storage Conditions
The powder is hygroscopic; it should be stored in an airtight container in a cool, dry 
place.
Incompatibilities
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Povidone is compatible in solution with a wide range of inorganic salts, natural and 
synthetic resins, and other chemicals. 
Safety
Povidone may be regarded as nontoxic since it is not absorbed from the 
gastrointestinal tract or mucous membranes.
CROSPOVIDONE
Nonproprietary Names
• BP: Crospovidone
• PhEur: Crospovidone
• USP-NF: Crospovidone
Synonyms
Crospovidonum; Crospopharm; crosslinked povidone; E1202; Kollidon CL; Kollidon CL-M; 
Polyplasdone XL; Polyplasdone XL-10; polyvinylpolypyrrolidone; PVPP; 1-vinyl-2-
pyrrolidinone homopolymer.
Chemical Name 
1-Ethenyl-2-pyrrolidinone homopolymer 
 Functional Category
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Tablet disintegrant.
Applications in Pharmaceutical Formulation or Technology
Crospovidone is a water-insoluble tablet disintegrant and dissolution agent used at 2–
5% concentration in tablets prepared by direct compression or wet- and dry-granulation 
method Crospovidone can also be used as a solubility enhancer dissolution rate.
Description
Crospovidone is a white to creamy-white, finely divided, free flowing, practically 
tasteless, odorless or nearly odorless, hygroscopic powder.
Stability and Storage Condition
Since crospovidone is hygroscopic, it should be stored in an airtight container in a 
cool, dry place.
Incompatibilities
Crospovidone is compatible with most organic and inorganic pharmaceutical 
ingredients. When exposed to a high water level, crospovidone may form molecular adducts 
with some materials.
Safety
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Crospovidone is used in oral pharmaceutical formulations and is generally regarded as
a nontoxic and nonirritant material.
MAIZE STARCH
Nonproprietary Names
• BP: Maize starch, Potato starch, Rice Starch, Tapioca Starch, Wheat Starch
• JP: Corn Starch, Potato Starch, Rice Starch, Wheat Starch
• PhEur: Maize Starch, Pea Starch, Potato Starch, Rice Starch, Wheat Starch
• USP-NF: Corn Starch, Potato Starch, Tapioca Starch, Wheat Starch
Synonyms
Amido; amidon; amilo; amylum; C*PharmGel; Eurylon; fecule; Hylon; maydis amylum; 
Melojel; Meritena; oryzae amylum; Pearl; Perfectamyl; pisi amylum; Pure-Dent; Purity 21; 
Purity 826; solani amylum; tritici amylum; Uni-Pure.
Chemical Name
          Starch
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Empirical Formula 
(C6H10O5)n where n = 300–1000.
Functional Category
Tablet and capsule diluent; tablet and capsule disintegrant; tablet binder; thickening 
agent.
Applications in Pharmaceutical Formulation or Technology
Starch is a versatile excipient used primarily in oral solid-dosage formulations where 
it is utilized as a binder, diluent, and disintegrant.
Description
Starch occurs as an odorless and tasteless, fine, white to off-white powder. It consists 
of very small spherical or ovoid granules or grains whose size and shape are characteristic for
each botanical variety.
Stability and Storage Conditions
Dry starch is stable if protected from high humidity. Starch is considered to be 
chemically and microbiologically inert under normal storage conditions. Starch solutions or 
pastes are physically unstable and are readily metabolized by microorganisms; they should 
therefore be freshly prepared when used for wet granulation. Starch should be stored in an 
airtight container in a cool, dry place.
Incompatibilities
Starch is incompatible with strongly oxidizing substances. Colored inclusion 
compounds are formed with iodine.
Safety
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Starch is an edible food substance, considered a food ingredient and not a food 
additive. It is regarded as an essentially nontoxic and non irritant material.
PREGELATINIZED STARCH
Nonproprietary Names
• BP: Pregelatinised Starch
• PhEur: Starch, Pregelatinised
• USP-NF: Pregelatinized Starch
Synonyms
Amylum pregelificatum; compressible starch; C*PharmGel; Instastarch; Lycatab C; Lycatab 
PGS; Merigel; National 78-1551; Pharma-Gel; Prejel; Sepistab ST200; Spress B820; Starch 
1500 G; Tablitz; Unipure LD; Unipure WG220.
Chemical Name
Pregelatinized starch
Empirical Formula
(C6H10O5)n where n = 300–1000.
Functional Category
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Tablet and capsule diluent; tablet and capsule disintegrant; tablet binder.
Applications in Pharmaceutical Formulation or Technology
Partially pregelatinized starch is a modified starch used in oral capsule and tablet 
formulations as a binder, diluent, and  Disintegrant.
Description
Pregelatinized starch occurs as a moderately coarse to fine, white to off-white colored 
powder. It is odorless and has a slight characteristic taste.
Stability and Storage Conditions
Pregelatinized starch is a stable but hygroscopic material, which should be stored in a 
well-closed container in a cool, dry place.
Safety
Pregelatinized starch and starch are widely used in oral solid-dosage 
formulations. Pregelatinized starch is generally regarded as a nontoxic and nonirritant 
excipient. However, oral consumption of large amounts of pregelatinized starch may 
be harmful.
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COLLOIDAL ANHYDROUS SILICA
Nonproprietary Names
• BP: Colloidal Anhydrous Silica
• JP: Light Anhydrous Silicic Acid
• PhEur: Silica, Colloidal Anhydrous
• USP-NF: Colloidal Silicon Dioxide
Synonyms
Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; colloidal silica; fumed silica; fumed silicon dioxide; 
hochdisperses silicum dioxid; SAS; silica colloidalis anhydrica; silica sol; silicic anhydride; 
silicon dioxide colloidal; silicon dioxide fumed; synthetic amorphous silica; Wacker HDK.
Chemical Name
 Silica
Empirical Name
CiO2
Functional Category
            Adsorbent; anticaking agent; emulsion stabilizer; glidant; suspending agent; 
tablet disintegrant, thermal stabilizer; viscosity-increasing agent.
Applications in Pharmaceutical Formulation or Technology
Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and food 
products; its small particle size and large specific surface area give it desirable flow 
characteristics that are exploited to improve the flow properties of dry powders in a number 
of processes such as tableting and capsule filling.
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Description
Colloidal silicon dioxide is a submicroscopic fumed silica with a particle size of about
15 nm. It is a light, loose, bluish-white-colored, odorless, tasteless, amorphous powder.
Stability and Storage Conditions
Colloidal silicon dioxide is hygroscopic but adsorbs large quantities of water without 
liquefying. When used in aqueous systems at a pH 0–7.5, colloidal silicon dioxide is effective 
in increasing the viscosity of a system. However, at a pH greater than 7.5 the viscosity 
increasing properties of colloidal silicon dioxide are reduced; and at a pH greater than 10.7 
this ability is lost entirely since the silicon dioxide dissolves to form silicates. Colloidal 
silicon dioxide powder should be stored in a well-closed container.
Incompatibilities
         Incompatible with diethylstilbestrol preparations.
Safety
Colloidal silicon dioxide is widely used in oral and topical pharmaceutical products 
and is generally regarded as an essentially nontoxic and nonirritant excipient. However, 
intraperitoneal and subcutaneous injection may produce local tissue reactions and/or 
granulomas. Colloidal silicon dioxide should therefore not be administered parenterally.
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MAGNESIUM STEARATE
Nonproprietary Names
• BP: Magnesium stearate 
• JP: Magnesium stearate
• PhEur: Magnesii stearas 
• USPNF: Magnesium stearate
Synonyms
Magnesium octadecanoate, octadecanoic acid, magnesium salt, stearic acid, magnesium salt.
Chemical Name 
Octadecanoic acid magnesium salt 
Empirical Formula 
C36H70MgO4
Functional Category
Tablet lubricant.
Applications in Pharmaceutical Formulation or Technology
Magnesium stearate is widely used as a lubricant.
Description
It is a very fine, light white, precipitated powder of low bulk density, having a 
faint odor of stearic acid with a characteristic taste and greasy to the touch and readily
adheres to the skin. Practically insoluble in ethanol, ether and water; slightly soluble 
in warm benzene.
Stability and Storage Conditions
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Magnesium stearate is stable and should be stored in a well-closed container in
a cool, dry place.
Incompatibilities
Incompatible with strong acids, alkalis, iron salts and strong oxidizing 
materials.
Safety
Oral consumption of large quantities may produce a laxative effect or mucosal
irritation.
CROSCARMELLOSE SODIUM
 Nonproprietary Names
• BP: Croscarmellose Sodium
• JP: Croscarmellose Sodium
• PhEur: Croscarmellose Sodium
• USP-NF: Croscarmellose Sodium
Synonyms
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Ac-Di-Sol; carmellosum natricum conexum; crosslinked carboxymethylcellulose sodium;
Explocel; modified cellulose gum; Nymcel ZSX; Pharmacel XL; Primellose; Solutab; 
Vivasol.
Chemical Name 
Cellulose, carboxymethyl ether, sodium salt, crosslinked 
Functional Category
Tablet and capsule disintegrant.
Applications in Pharmaceutical Formulation or Technology
Croscarmellose sodium is used in oral pharmaceutical formulations as a 
disintegrant for capsules, tablets, and granules.
Description
Croscarmellose sodium occurs as an odorless, white or grayish white powder.
Stability and Storage Conditions
Croscarmellose sodium is a stable though hygroscopic material. A model tablet 
formulation prepared by direct compression, with croscarmellose sodium as a disintegrant, 
Croscarmellose sodium should be stored in a well-closed container in a cool, dry place.
Incompatibilities
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The efficacy of disintegrants, such as croscarmellose sodium, may be slightly reduced
in tablet formulations prepared by either the wet-granulation or direct-compression process 
that contain hygroscopic excipients such as sorbitol. Croscarmellose sodium is not 
compatible with strong acids or with soluble salts of iron and some other metals such as 
aluminum, mercury, and zinc.
Safety
Croscarmellose sodium is mainly used as a disintegrant in oral pharmaceutical 
formulations and is generally regarded as an essentially nontoxic and nonirritant material. 
However, oral consumption of large amounts of croscarmellose sodium may have a laxative 
effect, although the quantities used in solid dosage formulations are unlikely to cause such 
problems.
HYPROMELLOSE
Nonproprietary Names
• BP: Hypromellose
• JP: Hypromellose
• PhEur: Hypromellose
• USP: Hypromellose
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Synonyms
Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; hypromellosum; Methocel; 
methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; Metolose; MHPC; 
Pharmacoat; Tylopur; Tylose MO. 
Chemical Name 
Cellulose hydroxypropyl methyl ether 
 Empirical Formula 
Partly O-methylated and O-(2-hydroxypropylated) cellulose.
Functional Category
Bioadhesive material; coating agent; controlled-release agent; dispersing 
agent; dissolution enhancer; emulsifying agent; emulsion stabilizer; extended-release 
agent; film-forming agent; foaming agent; granulation aid; modified-release agent; 
mucoadhesive; release-modifying agent; solubilizing agent; stabilizing agent; 
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suspending agent; sustained-release agent; tablet binder; thickening agent; viscosity-
increasing agent.
Applications in Pharmaceutical Formulation or Technology
Hypromellose is widely used in oral, ophthalmic, nasal, and topical pharmaceutical 
formulations.
Description
Hypromellose is an odorless and tasteless, white or creamy-white fibrous 
ogranular powder.
Stability and Storage Conditions
       Hypromellose powder is a stable material, it is hygroscopic after drying.
Incompatibilities
Hypromellose is incompatible with some oxidizing agents. Since it is 
nonionic, hypromellose will not complex with metallic salts or ionic organics to form 
insoluble precipitates.
Safety
Hypromellose is widely used as an excipient in oral, opthalmic, nasal, and 
topical pharmaceutical formulations. It is also used extensively in cosmetics and food 
products.
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EUDRAGIT® L 30 D-55
Nonproprietary Names
• Ph. Eur.: Methacrylic Acid - Ethyl Acrylate Copolymer (1:1) Dispersion 30%
• USP/NF: Methacrylic Acid Copolymer Dispersion - NF 
• JPE: Methacrylic Acid Copolymer LD
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Chemical name: 
              Poly(methacrylic acid-co-ethyl acrylate) 1:1
Empirical Formula
Acrylates Copolymer 
Functional catagory
EUDRAGIT® L 30 D-55 is the aqueous dispersion 30% of anionic polymers 
with methacrylic acid as a functional group.
Applications in Pharmaceutical Formulation or Technology
 Effective and stable enteric coatings with a fast dissolution in the upper Bowel
 Granulation of drug substances in powder form for controlled release
 Site specific drug delivery in intestine by combination with EUDRAGIT® S 
grades
 Variable release profiles
Description
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It is a milky-white liquid of low viscosity with a faint characteristic odour.
POLYETHYLENE GLYCOL 
Synonyms
Breox PEG; Carbowax; Hodag PEG; Lutro E; PEG; polyoxyethylene glycol.
Chemical name 
¬ -Hydro-α-hydroxy-poly(oxy-1,2-ethane-1-yl)
Empirical formula   
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HOCH2(CH2OCH2)mCH2OH
Where m represents the average number of oxyethylene groups 
Molecular weight
380 - 420
Functional category
Ointment base; plasticizer; solvent; suppository base; tablet and capsule 
lubricant.
Applications in pharmaceutical formulation or technology
 Polyethylene glycols are widely used in a variety of pharmaceutical 
formulations including parenteral, topical, ophthalmic, oral and rectal 
preparations.
 Although they do not readily penetrate the skin, polyethylene glycols 
are water soluble and as such are easily removed from the skin by 
washing; they are therefore useful as ointment bases. 
 Mixtures of polyethylene glycols can be used as suppository bases.  
Disadvantages of using polyethylene glycols are : they are chemically 
more reactive than fats. 
 Aqueous polyethylene glycol solutions can be used either as 
suspending agents or to adjust the viscosity and consistency of other 
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suspending vehicles.  When used in conjunction with other emulsifiers,
polyethylene glycols can act as emulsion stabilizers.
 Liquid polyethylene glycols are used as water-miscible solvents for the
contents of soft gelatin capsules.  However, they may cause hardening 
of the capsule shell by preferential absorption of moisture from gelatin 
in the shell.
 When used for thermoplastic granulations, a mixture of the powdered 
constituents with 10-15 % w/w PEG 6000 is heated to 70-75oC.  the 
mass becomes paste-like and forms granules if stirred while cooling.
 In film coatings, solid grades of polyethylene glycol can be used alone 
for the film coating of tablets or can be useful as hydrophilic polishing 
materials.  Solid grades are also widely used as plasticizers in 
conjunction with film forming polymers.
 Polyethylene glycol grades with molecular weights of 6000 and above 
can be used as lubricants, particularly for soluble tablets.
Description
The USPNF XVII describes polyethylene glycol as being an addition polymer of 
ethylene oxide and water.  Polyethylene glycol grades 200-600 are liquids whilst grades 1000
and above are solids at ambient temperatures.
Moisture content
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Liquid polyethylene glycols are very hygroscopic, although hygroscopicity decreases 
with increasing molecular weight.  Solid grades, e.g PEG 4000 and above, are non 
hygroscopic. 
Refractive index
nD
25
= 1.459 for PEG 200
nD
25
= 1.463 for PEG 300
nD
25
= 1.465 for PEG 400
nD
25
= 1.467 for PEG 600
Solubility
 All grades of polyethylene glycol are soluble in water and miscible in 
all proportions with other polyethylene glycols (after melting, if 
necessary).
 Aqueous solutions of higher molecular weight grades may form gels; 
Liquid polyethylene glycols are soluble in acetone, alcohols, benzene, 
glycerin and glycols. 
 Solid polyethylene glycols are soluble in acetone, soluble in aliphatic 
hydrocarbons and there, but insoluble in fats, fixed oils and mineral oil.
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MATERIAL AND METHODS
MATERIALS USED:
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List of materials used for formulation of Mycophenolate sodium 360mg Delayed –
Release Tablets
S.NO INGREDIENTS FUNCTION SUPPLIER
1. Mycophenolate sodium BP Active ingredients Biocon Ltd.
2. Lactose monohydrate BP Diluent Signet
3. Crospovidone (XL 10) BP Disintegrant FMC Bio Polymer
4. Povidone K 30 BP Binder BASF
5. Pregelatinised starch BP Diluent / Disintegrant RanQ Remidies
6. Maize Starch BP Diluent / Disintegrant Maize Products
7. Croscarmellose sodium BP Disintegrant FMC Bio Polymer
8. Colloidal anhydrous silica BP Glidant Signet
9. Magnesium stearate BP Tablet Lubricant Nitika
10. Hypromellose (HPMC) Film forming agent Colorcon
11. Polyethylene Glycol Plastisizer. Vasudha
12. Isopropyl alcohol BP Non aqueous solvent Magnus
Pharmaceutical
13. Dichloromethane BP Non aqueous solvent
14. Eudragit  L30 D – 55  MS Enteric  Film  forming
agent
Evonik Products
15. Purified Talc BP Smoothening agent. Signet
16. Titanium dioxide BP Opacifier Kronos
17. Ferric oxide yellow USP Colorant Kronos
18. Ferric oxide red USP Colorant Kronos
19. Sodium hydroxide BP Alkaniser RanQ Remidies
20. Purified water Aqueous solvent In House
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EQUIPMENTS USED: 
List equipments used for formulation of mycophenolate sodium 360mg Delayed – 
Release tablets.
S.NO EQUIPMENTS MANUFACTURER
1. Electronic Weighing Scale - 220 g Shimadzu,  Japan
2. Electronic Weighing Scale –5kg & 
30kg
Essae
3. Disintegration tester Electrolab
4. Tapped volumeter Erweka, Germany
5. Electromagnetic Sieve shaker Electrolab
6. IR-Moisture Analyzer Essae Taroka
7. Bin Blender 30/10/5/2 Liters Sams Techno Mech
8. Rapid Mixer Granulator  Sams Techno Mech
9. Fluid Bed Drier Pam Glatt
10. Multimill Sams Techno Mech
11. Vibro sifter (30’ , 750 mm) Sams Techno Mech
12. Hardeness Tester Erweka, Germany
13. Friabilator Electrolab
14. Digital Vernier Caliber Mitutoyo
15. Mechanical Stirrer Remi, Mumbai
16. PH Meter Eutech
17. De- Humidifier Novita
18. Compression Machine -10 station Pacific Tools
19. Coating machine – Conventional Sams Techno Mech
20. HPLC Shimadzu Model No.SPD-10A
21. UV visible spectrophotometer Shimadzu,  Japan
22. Stability chamber- 40°C/75%RH Thermolab, Maharashtra
23. Stability chamber- 50°C/90%RH Thermolab, Maharashtra
PREFORMULATION STUDY
                         Preformulation testing is the first step in the development of dosage 
forms of a drug substance. It can be defined as an investigation of physical and chemical 
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properties of a drug substance alone and when combined with excipients. The overall 
objective of Preformulation studies is to generate information useful to the formulator in 
developing a stable dosage forms.
API Characterization
Pre-formulation may be described as a phase of the research and development 
process, where the formulation scientist characterizes the physical, chemical and mechanical 
properties of new drug substances, in order to develop stable, safe and effective dosage 
forms. Pre-formulation studies were performed on the drug which includes solubility, Bulk 
density, Tapped density, Compatibility. 
Physical Appearance
The API was observed for its color and physical state
 Solubility
 Solubility is the property of a solid, liquid, or gaseous chemical substance called 
solute to dissolve in a liquid solvent to form a homogeneous solution of the solute of the 
solute in the solvent. The solubility of a substance fundamentally depends on the used solvent
as well as on temperature and pressure. The specified quantity of sample (1gm) was added 
into different quantity of solvent (methanol, alchol, chloroform, water, acetone, ethyl acetate) 
in room temperature.
Loss of drying:
  Loss on drying was done using IR Moisture analyzer to check the moisture content 
in the test sample. The sample of about 1-2gm taken for analysis.
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Bulk Density
  The density of a powder is determined using volume meter. A known weight of 
sample is placed into a measuring cylinder and measured untapped Volume and its weight.
                    Pour (or Bulk) density=mass/untapped Volume.
Tapped density
  Known weight of sample is placed into a measuring cylinder and ‘tapped’ 
(mechanically raised and lowered a set distance) until a consistent volume is reached which 
corresponds to the maximum packing density of the material.
                    Tapped density= mass/tapped volume
Hausner ratio and Carr’s index
 The Hausner ratio and Carr’s index are both measures of the flow
properties of powders. 
 A Hausner ratio of <1.25 indicates a powder that is free flowing
                                     Whereas >1.25 indicates poor flow ability. 
 The smaller the Carr’s index the better the flow properties.
 5-15 indicates excellent 12-16 good, 18-21 fair and >23 poor flow.
DRUG EXCIPIENTS COMPATIBILITY STUDIES
Drug–Excipient Compatibility Study
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The successful formulation of a stable and effective solid dosage form depends on the 
careful selection of the excipients that are added. The commonly used excipients are blended 
with the API in the varying ratios and subjected to accelerated condition (3 months in 40°C / 
75 % RH), and at stress condition (1 month in 50°C / 90 % RH), the sample are monitored for
any change in physical state, colour, odor, loss on drying and related substances. Any 
excipients contributing to such a change shall not be used in the formulation.
Selection of Excipients
The excipients are selected based on the excipients of reference product, apart from 
the reference product excipients other excipients are selected based on the proposed 
composition & possible use of them.
Sample preparation
Binary mixtures of the drug and excipients are prepared by placing the accurately 
weighed amounts of the drug and excipients in polybag and mixed till homogenous mixture is
achieved. Then, these mixtures are filled in vials and closed with bromo butyl rubber stoppers
& crimped with tear off clear lacquer aluminum seals. These samples are charged at 
50°C/90% RH and 40°C/75% RH conditions.
Storage conditions
Table No:  Stability conditions and parameters for Drug–Excipients Compatibility 
Study
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Sample analysis
All vials are inspected for the appearance, color and odour. The samples removed 
from 40°C/75% RH and 50°C/90% RH are analyzed as per the parameters mentioned in the 
above table.
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Initial
40°C/75% RH 50°C/90%RH
1month 2month 3month 1month
1. Physical
appearance     
2. Related Substances     
3. Assay     
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FORMULATION DEVOLPMENT FOR CORE TABLET TRIALS
S.NO NAME OFINGREDIENT
QTY/TABLET (mg)
F1 F2 F3 F4
Dry mix
1. Mycophenolate sodium BP* 384.70 384.70 384.70 384.70
2. Lactose monohydrate BP** 134.80 130.65 120.60 122.20
3. Croscarmellose Sodium BP 16.35 16.35 20.40 -----
4. Crospovidone (XL10) BP ----- ----- ----- 16.80
Binder
5. Povidone K 30 BP 4.80 6.50 6.50 6.50
6. Isopropyl alcohol BP 140.00 140.00 140.00 140.00
Lubrication
7. Maize starch BP 12.00 12.00 18.00 -----
8. Pregelatinised starch BP ----- ----- ----- 20.00
9. Colloidal anhydrous silica BP 3.15 4.20 4.20 4.20
10. Magnesium stearate BP 4.20 5.60 5.60 5.60
Total Core Tablet weight 560.00
*Actual quantity of Mycophenolate sodium BP to be dispensed in based on actual %purity. 
** Quantity of excipients should adjust to the target filled weight.
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FORMULATION DEVOLPMENT FOR SEAL COATING TRIALS
S.NO NAME OFINGREDIENT
QTY/TABLET (mg)
S 1
2.5%
S 2
2.86%
S 3
3.04%
S 4
3.21%
1 Hypromellose  BP(5cps) 11.38 13.00 13.81 14.62
2 Polyethylene glycol BP 2.62 3.00 3.19 3.38
3 Isopropyl alcohol BP 140.00 160.00 170.00 180.00
4 Dichloromethane BP 140.00 160.00 170.00 180.00
Seal coating weight gain         14.00 16.00 17.00 18.00
Total seal coated tablet weight 574.00 576.00     577.00 578.00
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FORMULATION DEVOLPMENT FOR ENTERIC COATING TRIALS
S.N
O
NAME OF
INGREDIENT
QTY/TABLET (Mg/tab)
E 1
8.68
%
E 2
9.55
%
E 3
10.42
%
E 4
11.28%
E 5
12.15
%
1.
Eudragit L30 D – 55 MS 
(100mg eq to 30mg solid)
116.62 128.38 140.00 151.62 163.38
2. Polyethylene glycol BP 4.00 4.40 4.80 5.20 5.60
3. Purified Talc BP 7.50 8.25 9.00 9.75 10.50
4. Titanium dioxide BP 2.50 2.75 3.00 3.25 3.50
5. Ferric oxide yellow USP 0.50 0.55 0.60 0.65 0.70
6. Ferric oxide red USP 0.12 0.13 0.15 0.16 0.18
7. Sodium hydroxide BP 0.38 0.41 0.45 0.49 0.52
8.
Water for NAOH BP
 ( 10 % w/w)
3.75 4.13 4.50 4.90 5.20
9.
Purified water BP for Color 
suspension
71.22 78.40 85.50 92.60 99.77
Enteric coating weight gain 50.00 55.00 60.00 65.00 70.00
Total coated tablet weight 626.00 631.00     636.00 641.00 646.00
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FORMULATION DEVELOPMENT FOR COMPARABLE DISSOLUTION PROFILE 
TRIALS (CDP)
S.NO NAME OFINGREDIENT
QTY/TABLET (mg)
D1 D2 D3 D4
Core Tablet Formula
Dry mix
1. Mycophenolate sodium BP* 384.70 384.70 384.70 384.70
2. Lactose monohydrate BP** 120.58 118.95 118.30 117.50
3. Crospovidone (XL10) BP 16.80 16.80 16.80 16.80
Binder
4. Povidone K 30 BP 8.12 9.75 10.40 11.20
5. Isopropyl alcohol BP 140.00 140.00 140.00 140.00
Lubrication
6. Pregelatinised starch BP 20.00 20.00 20.00 20.00
7. Colloidal anhydrous silica BP 4.20 4.20 4.20 4.20
8. Magnesium stearate BP 5.60 5.60 5.60 5.60
Total Core Tablet weight 560.00
Seal Coating Formula
9. Hypromellose  BP(5cps) 
13.00 13.00 13.00 13.00
10. Polyethylene glycol BP
3.00 3.00 3.00 3.00
11. Isopropyl alcohol BP 160.00 160.00 160.00 160.00
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12. Dichloromethane BP
160.00 160.00 160.00 160.00
Seal coating weight gain 16.00
Total seal coated Tablet weight 576.00
*Actual quantity of Mycophenolate sodium BP to be dispensed in based on actual %purity. 
** Quantity of excipients should adjust to the target filled weight.
S.NO NAME OFINGREDIENT
QTY/TABLET (mg)
D1 D2 D3 D4
Enteric Coating Formula
1. Eudragit L30 D – 55 MS 
(100mg eq to 30mg solid)
140.00 140.00 140.00 140.00
2. Polyethylene glycol BP 4.80 4.80 4.80 4.80
3. Purified Talc BP 9.00 9.00 9.00 9.00
4. Titanium dioxide BP 3.00 3.00 3.00 3.00
5. Ferric oxide yellow USP 0.60 0.60 0.60 0.60
6. Ferric oxide red USP 0.15 0.15 0.15 0.15
7. Sodium hydroxide BP 0.45 0.45 0.45 0.45
8. Water for NAOH BP
 ( 10 % w/w)
4.50 4.50 4.50 4.50
9. Purified water BP for Color 85.50 85.50 85.50 85.50
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suspension
Enteric coating weight gain 60.00
Total Enteric Coated Tablet weight 636.00
INFORMATION ON DEVELOPMENT STUDIES:
Manufacturing procedure for Mycophenolate sodium tablets was optimized at various
steps of formulation development.  Studies were conducted using the most commonly used
conventional wet granulation process. Results of wet granulation trials were encouraging. In-
process parameters of compression, seal coating and enteric coating were satisfactory.
PROCESS FLOW DIAGRAM OF WET GRANULATION
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MANUFACTURING PROCESS 
1. POTENCY CALCULATION
              *Amount of the Mycophenolate sodium BP based on the 100% potency on 
anhydrous basis.  Quantity of Mycophenolate sodium BP shall be calculated by using the 
formula given below.
Quantity Mycophenolate = Label claim (in mg) x 100 x 100
sodium MS                                  Assay x (100 – LOD)
**Actual Quantity of Lactose monohydrate BP shall be calculated by using the 
formula given below.
Standard Quantity of (Mycophenolate sodium MS + Lactose monohydrate BP) - Actual 
Quantity of Mycophenolate sodium MS 
Mycophenolate sodium 384.7mg = Mycophenolic acid 360mg
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2. GENERAL INSTRUCTION
 Carry out all manufacturing activities at NMT 25°C & NMT 60% RH.
 Use talc free gloves and nose masks while all manufacturing activities.  
3. DISPENSING
Carry out the dispensing of API and excipients of the batch in Dispensing Booth. 
Packed in virgin polythene bag separately for each material.
4. DRY MIX SIFTING
i. Use Stainless Steel (S.S.) sieve of #30
ii. Collect sifted items in In-Process Containers (IPCs) lined with virgin polythene 
bag separately for each material. 
iii. Check the cleanliness and the integrity of the sieves before and after use.
iv. Use talc free gloves and nose masks while sieving the materials.  
Mycophenolate sodium BP
Sift using 30 # S.S. Sieve and collect in the S.S. bin.
Lactose monohydrate BP
Sift using 30 # S.S. Sieve and collect in the S.S. bin.
Maize starch BP
Sift using 30 # S.S. Sieve and collect in the S.S. bin.
Crospovidone (XL 10) BP 
Sift using 30 # S.S. Sieve and collect in the S.S. bin.
4. DRY MIXING 
Load the above sifted material in to Bin Blender and mix for 15 min at 25 RPM 
speed.
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5. BINDER
Dispense and take Isopropyl alcohol BP. Dissolve Povidone BP (K 30) under 
mechanical stirring for 30 minutes.
6. WET GRANULATION
 Add 70 % of binder to dry mix present in RMG under slow speed for 2 
minutes. Rake the mass in RMG, if necessary. 
 Add remaining quantity of binder, continue mixing for 4 - 5 minutes with 
impeller at SLOW speed and chopper (if required) until desired wet mass 
obtained. 
 If required add additional quantity of Isopropyl alcohol BP and mix for two 
more minutes.
7. DRYING OF GRANULES
Discharge the wet mass from RMG into Fluid Bed Drier Bowl by opening the 
discharge port and operating the impeller and chopper at SLOW speed. Operate the FBD as 
described in the Standard operating procedure.
CYCLE I: Distribute the material uniformly in the FBD bowl using S.S. paddle. Start the 
FBD and air-dry the wet mass without application of heat (steam valve to be kept closed) for 
15 minutes.
CYCLE II: Rake the wet mass and continue drying the wet granules in FBD at an inlet 
temperature of 40 - 60°C (set at 55°C) for 30 minutes.  Record the LOD result.
 LOD Limit: Between 1.0 – 2.5 % W/W (target 1.5 % w/w) 
LOD parameter :(105ºC)
If the LOD value obtained is within the specified range, take samples for LOSS ON 
DRYING (LOD) and test LOD at 105˚ C by IR moisture balance. Record the LOD result.
80
------------------------------------------------------------------------------------------------------------
Formulation Development and Evaluation
Mycophenolate Sodium Delayed-Release Tablets 360mg
------------------------------------------------------------------------------------------------------------
8. DRY SIFTING
Sift the dried granules through 20 # SS sieve using vibratory sifter. Collect the 
retention in a poly bag.
9. DRY MILLING
Pass the retention granules through multimill fitted with 1.5 mm screen Knives 
forward at slow speed. Collect the milled granules in the IPC bin and transfer to vibratory 
sifter. Repeat the dry shifting and do this process until the   end of retention. Record the 
milling time and weighing detail of bin.
10. PRE LUBRICATION  
i. Use Stainless Steel (S.S.) sieves of #30and #40
ii. Collect sifted items in In-Process Containers (IPCs) lined with virgin 
polythene bag separately for each material. 
iii. Check the cleanliness and the integrity of the sieves before and after use.
iv. Use talc free gloves and nose masks while sieving the materials.  
v. Transfer sifted Croscarmellose Sodium BP and Colloidal silicondioxide 
BP into the blender containing dried and milled granules.
Croscarmellose Sodium BP
Sift using 40 # S.S. Sieve and collect in the S.S. bin.
Colloidal silicondioxide BP
Sift using 30# S.S. Sieve and collect in the S.S. bin.
11.  PRE LUBRICATION BLENDING 
Load the above sifted material in to Bin Blender and mix for 15 min at slow speed.
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12.  LUBRICATION 
i. Use Stainless Steel (S.S.) sieve of #60
ii. Collect sifted items in In-Process Containers (IPCs) lined with virgin polythene 
bag separately for each material. 
iii. Check the cleanliness and the integrity of the sieves before and after use.
iv. Use talc free gloves and nose masks while sieving the materials. 
v. Transfer sifted Magnesium Stearate BP into the Pre lubricated blend. 
Magnesium stearate BP  
Sift using 60 # S.S. Sieve and collect in the S.S. bin.
13.  LUBRICATION BLENDING
Load the above sifted material in to Bin Blender and Blend for 3 min at slow speed.
Record the % yield of lubricated granules. 
14. COMPRESSION (PUNCH&DIES):  
i. Set the tablet compression machine by using respective punches and dies.
ii. Set the Compression machine for the following parameters
iii. Results for each parameter as per the Acceptance criteria shall be recorded for
each batch at different hopper levels.
iv. Carry out all compression activities at NMT 25°C & NMT 60% RH.
15. PUNCH&DIES DETAILS  
Upper Punch: 11.50 mm circular shape, concave plain on surface.
Lower Punch: 11.50 mm circular shape, concave plain on surface.
Dies               : 11.50 mm.
In process Physical parameters Specifications (core):
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Parameters Specification
Appearance White to Off white color, circular shape, biconvex uncoated
tablets plain on both side.
Target weight 560.0 mg
Average weight 560.0 mg ± 2.0 %
Uniformity of weight Average weight ± 4.0%
Diameter 11.5 ± 0.2mm
Thickness 5.70 ± 0.2mm
Hardness 40 to 100 N
Disintegration Time NMT 15 minutes
Friability NMT 1% w/w
14. SEAL COATING SOLUTION PREPARATION
a) 10% overage is taken for compensating loss on coating. 
b) Disperse Hypromellose BP (15 cps) in Isopropyl alcohol BP and stir for 15 
minutes.
c) Dissolve Polyethylene glycol BP in Methylene dichloride BP. 
d) Transfer the above two solution into the same beaker and stir for 15 minutes.
e) Prepared seal coating solution was filter with nylon cloth.
f) Store the filtered seal coating solution into well closed air tight container. 
15. SEAL COATING OPERATION 
i. Load uncoated tablets into coating pan and warm the bed temperature between
35-50°C.
ii. Load the coating suspension in coating suspension storage tank and start 
stirrer.
iii. Check the uniformity of mass of 20 coated tablets
iv. Operate the coating pan as described by the below Standard Operating 
Procedure
S.NO
.
SEAL COATING PARAMETERS LIMITS
1. Pan speed 3 to 6 RPM
2. Inlet air temperature 40 to 50°C
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3. Exhaust air temperature 35 to 50 ° C
4. Automizing air pressure 2.0 to 4.0 kg/cm2
5. Spray gun nozzle diameter 1.5 mm
6. Distance between spray gun & surface of the tablet bed 16 -20 inches
In process Physical parameters Specifications (Seal coating):
Parameters Specification
Description of tablets
White to off white color, circular shape, and biconvex seal 
coated tablets plain on both sides.
Target weight 576.0 mg
Average weight 576.0 mg ± 2.0 %
Uniformity of weight. Average weight ± 4.0%
Diameter 11.6 ± 0.2 mm
Thickness 5.8 ± 0.2mm
Disintegration Time      NMT 15 minutes
16. ENTERIC COATING SOLUTION PREPARATION
i. 10% overage is taken for compensating loss on coating. 
ii. Disperse Eudragit L30 D – 55 IH in purified water BP.
iii. Dissolve sodium hydroxide BP in purified water. Slowly add this solution into 
above dispersed solution. After reaching 5.2 PH sodium hydroxide solution 
should not be added.
iv. Add Talc BP, Titanium dioxide BP, Ferric oxide yellow USP, Ferric oxide red 
USP and Polyethylene glycol BP in purified water under colloidal mill. After 20 
minutes transfer into above solution and stir for 10 minutes.
v. Prepared enteric coating solution was filter with nylon cloth.
vi. Store the filtered enteric coating solution into well closed air tight container.
17. ENTERIC COATING OPERATION 
i. Load seal coated tablets into coating pan and warm the bed temperature between 
35-50°C.
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ii. Load the coating suspension in coating suspension storage tank and start stirrer.
iii. Check the uniformity of mass of 20 coated tablets.
iv. Operate the coating pan as described by the below Standard Operating Procedure.
S.NO. ENTERIC COATING PARAMETERS LIMITS
1. Pan speed 3 to 6 RPM
2. Inlet air temperature 40 to 50°C
3. Exhaust air temperature 35 to 50 ° C
4. Automizing air pressure 2.0 to 4.0 kg/cm2
5. Spray gun nozzle diameter 1.5 mm
6. Distance between spray gun & surface of the tablet bed 16 -20 inches
In process Physical parameters Specifications (Enteric coating):
Parameters Specification
Description of tablets
Peach color, circular shape, and biconvex enteric coated tablets
plain on both sides.
Target weight 636.00 mg
Average weight 636.00 mg ± 2.0 %
Uniformity of weight. Average weight  ± 4%
Diameter 11.8 ± 0.2mm
Thickness 6.0 ± 0.2mm
Disintegration Time    
a) 0.1 M Hydrochloric acid -  No crack should be observed in 2   
hours.
b) PH 6.8 phosphate buffer      -    Disintegration NMT 45 minutes.
18. CONTAINER CLOSURE SYSTEM
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The  Tablets  are  packed  in  Alu-Alu  blisters  and  PVDC  blisters.  These  package
materials are commonly used for oral solid forms and no special interaction studies were
performed. The packaging materials are obtained from reliable, qualified suppliers. Results of
stability studies confirm suitability of chosen primary packaging materials.
19. ALU/ALU BLISTER PACKING: 
I. Set the sealing temperature of Alu-Alu Blister packing machine at 180 to 190ºC 
II. Run the machine and pack the tablets. Take samples and send for leak test. 
Sampling quantity: 5 Blister.
S.NO PARAMETERS OBSERVATION
1 Thickness (mm) 6.2 mm 
2 Diameter (mm) 11.9 mm
20. LEAK TEST PROCEDURE:
 Place the blisters to be leak tested into Desiccators containing a blue dye solution.
 Close the lid.
 Test pressure will be -60 Kpa for 60 seconds
 Observation should be At 180 to 190ºC - Not a single strip fail.
 
21. DISSOLUTION APPARATUS PARAMETERS
i. Method                    :  USP dissolution apparatus-ll (paddle) method
ii. Temperature             :  37oC ±  0.5˚C  
iii. Dissolution medium :  pH 6.8 Phosphate buffer
iv. Volume                     :  1000ml
v. RPM                         :  50
RESULT AND DISCUSSION
86
------------------------------------------------------------------------------------------------------------
Formulation Development and Evaluation
Mycophenolate Sodium Delayed-Release Tablets 360mg
------------------------------------------------------------------------------------------------------------
EVALUATION OF INNOVATOR PRODUCT
Product Name Myfortic®-360
Brand Name Novartis pharma stein AG
Lot No S0612
Exp. Date October 2014
Strength 360mg
Description Peach color, circular shape, and biconvex 
enteric coated tablets plain on both sides.
Storage Conditions Store at a temperature below 30°C (86 F); 
Brief exposure to 40°C does not adversely 
affect the product. Protect from moisture.
Physical Parameter
Average weight of coated tablet(mg) 640.00 639.00 641.00
Core weight/Enteric weight (mg) 563/76 559/78 562/79
Thickness of coated tablet (mm) 6.05 5.99 6.12
Thickness of core tablet (mm) 5.68 5.66 5.71
Hardness (N) 56 63 71
Diameter mm 11.84 11.79 11.87
Disintegration 
Time 
0.1 M Hydrochloric acid No crack observed in 2 hours.
PH 6.8 phosphate buffer     28 minutes 33 seconds to 34 minutes 56 seconds.
Package Evaluation
Pack Size 10 Tablets
Packing Container Alu-Alu blisters
Printed Leaflet Printed Leaflet attached on Carton Box
Inactive Ingredients
Lactose anhydrous, Maize starch, Povidone K 30, Croscarmellose Sodium, Colloidal silicon 
dioxide, Magnesium stearate, HPMC phthalate, Titanium dioxide, Ferric oxide red
INNOVATOR DISSOLUTION PROFILE
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S.N
O Time in Minutes
Innovator-Sample 
Myfortic® 360
Lot No:S0612
1.
0 0.00
2.
10 1.98
3.
20 30.94
4.
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60 99.58
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DRUG-EXCIPIENTS COMPATIBILITY STUDY
Sample & Ratio Interval &Condition
Related substances
Im
p A
(%)
Im
p B
(%)
Im
p C
(%)
Imp
D
(%)
Unknow
n Imp E
(%)
Total
Imp
(%)
Mycophenolate 
sodium
1:1
INITIAL 0.0
1 ND ND 0.01 ND 0.02
40
°
C
/ 7
5%
R
H
1M 0.0
1 ND ND 0.01 ND 0.02
2M 0.0
1 ND ND 0.01 ND 0.02
3M 0.0
1 ND
0.0
1 0.01 ND 0.03
1M 50°C/90%RH 0.0
1 ND ND 0.01 ND 0.02
Mycophenolate 
Sodium+ 
Lactosemonohydrat
e
1:1
INITIAL 0.0
1
0.0
1
0.0
1 0.01 ND 0.04
40
°
C
/ 7
5%
R
H
1M 0.0
1
0.0
1
0.0
1 0.01 ND 0.04
2M 0.0
1
0.0
1
0.0
1 0.01 ND 0.04
3M 0.0
1
0.0
1
0.0
1 0.01 0.01 0.05
1M 50°C/90%RH
0.0
1
0.0
1
0.0
1 0.01 ND 0.04
Mycophenolate 
Sodium + 
Crospovidone
1:1
INITIAL 0.0
1
0.0
1
0.0
1 0.01 ND 0.04
40
°
C
/ 1M 0.0
1
0.0
1
0.0
1 0.01 ND 0.04
2M 0.0 0.0 0.0 0.01 ND 0.04
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75
%
R
H 1 1 1
3M 0.0
1
0.0
1
0.0
1 0.01 0.01 0.05
1M 50°C/90%RH 0.0
1
0.0
1
0.0
1 0.01 ND 0.04
Sample &
Ratio Interval &Condition
Related substances
Im
p A
(%)
Im
p B
(%)
Im
p C
(%)
Imp
D
(%)
Unknow
n Imp E
(%)
Total
Imp
(%)
Mycophenolat
e Sodium + 
Povidone K30
1:1
INITIAL 0.01 0.01
0.0
1 0.01 ND 0.04
40
°
C
/ 7
5%
R
H
1M 0.01 0.01
0.0
1 0.01 ND 0.04
2M 0.01 0.01
0.0
1 0.01 ND 0.04
3M 0.01 0.01
0.0
1 0.01 0.01 0.05
1M 50°C/90%RH 0.01 0.01
0.0
1 0.01 ND 0.04
Mycophenolat
e Sodium + 
PGS
1:1
INITIAL 0.01 0.01
0.0
1 0.01 ND 0.04
40
°
C
/ 7
5%
R
H 1M 0.01 0.01
0.0
1 0.01 ND 0.04
2M 0.01 0.0
1
0.0
1
0.01 ND 0.04
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3M 0.01 0.01
0.0
1 0.01 0.01 0.05
1M 50°C/90%RH 0.01 0.01
0.0
1 0.01 ND 0.04
Mycophenolat
e Sodium  + 
Colloidal 
unhydrous 
silica
1:1
INITIAL 0.01 0.01
0.0
1 0.01 ND 0.04
40
°
C
/ 7
5%
R
H
1M 0.01 0.01
0.0
1 0.01 ND 0.04
2M 0.01 0.01
0.0
1 0.01 ND 0.04
3M 0.01 0.01
0.0
1 0.01 0.01 0.05
1M 50°C/90%RH 0.01 0.01
0.0
1 0.01 ND 0.04
Sample &
Ratio Interval &Condition
Related substances
Imp
A
(%)
Imp
B
(%)
Imp
C
(%)
Imp
D
(%)
Unknow
n Imp E
(%)
Total
Imp
(%)
Mycophenolat
e Sodium + 
Mg Stearate
1:1
INITIAL 0.01 0.01 0.01 0.01 ND 0.04
40
°
C
/ 7
5%
R
H 1M 0.01 0.01 0.01 0.01 ND 0.04
2M 0.01 0.01 0.01 0.01 ND 0.04
3M 0.01 0.01 0.01 0.01 0.01 0.05
1M 50°C/90%RH 0.01 0.01 0.01 0.01 ND 0.04
Lactose mono 
INITIAL 0.01 0.01 ND ND ND 0.02
40 1M 0.01 0.01 ND ND ND 0.02
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hydrate
°
C
/ 7
5%
R
H
2M 0.01 0.01 ND ND ND 0.02
3M 0.01 0.02 ND ND ND 0.03
1M 50°C/90%RH 0.01 0.01 ND ND ND 0.02
Crospovidone
INITIAL 0.01 ND 0.01 0.01 ND 0.03
40
°
C
/ 7
5%
R
H 1M 0.01 ND 0.01 0.01 ND 0.03
2M 0.01 ND 0.01 0.01 ND 0.03
3M 0.01 ND 0.01 0.02 ND 0.04
1M 50°C/90%RH 0.01 ND 0.01 0.01 ND 0.03
Sample
& Ratio Interval &Condition
Related substances
Imp
A
(%)
Imp
B
(%)
Imp
C
(%)
Imp
D
(%)
Unknown
Imp E
(%)
Total
Imp
(%)
Povidone 
K30
INITIAL 0.01 0.01 ND ND ND 0.02
40
°
C
/ 7
5%
R
H 1M 0.01 0.01 ND ND ND 0.02
2M 0.01 0.01 ND ND ND 0.02
3M 0.01 0.02 ND ND ND 0.03
1M 50°C/90%RH 0.01 0.01 ND ND ND 0.02
PGS INITIAL 0.01 ND 0.01 0.01 ND 0.03
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40
°
C
/ 7
5%
R
H 1M 0.01 ND 0.01 0.01 ND 0.03
2M 0.01 ND 0.01 0.01 ND 0.03
3M 0.01 ND 0.01 0.02 ND 0.04
1M 50°C/90%RH 0.01 ND 0.01 0.01 ND 0.03
Colloidal 
unhydrou
s Silica
INITIAL 0.01 0.01 ND ND ND 0.02
40
°
C
/ 7
5%
R
H 1M 0.01 0.01 ND ND ND 0.02
2M 0.01 0.01 ND ND ND 0.02
3M 0.01 0.02 ND ND ND 0.03
1M 50°C/90%RH 0.01 0.01 ND ND ND 0.02
Sample &
Ratio Interval &Condition
Related substances
Imp
A
(%)
Imp
B
(%)
Imp
C
(%)
Imp
D
(%)
Unknow
n Imp E
(%)
Total
Imp
(%)
Magnesium 
Sterate
INITIAL 0.01 ND 0.01 0.01 ND 0.03
40
°
C
/ 7
5%
R
H 1M 0.01 ND 0.01 0.01 ND 0.03
2M 0.01 ND 0.01 0.01 ND 0.03
3M 0.01 ND 0.01 0.02 ND 0.04
1M 50°C/90%RH 0.01 ND 0.01 0.01 ND 0.03
Mycophenolat INITIAL 0.07 0.03 0.03 0.04 0.01 0.18
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e Sodium+ All
core 
formulation 
Excipents
1:1
40
°
C
/ 7
5%
R
H 1M 0.07 0.03 0.03 0.04 0.01 0.18
2M 0.07 0.03 0.03 0.04 0.01 0.18
3M 0.07 0.03 0.03 0.04 0.02 0.19
1M 50°C/90%RH 0.07 0.03 0.03 0.04 0.01 0.18
All core 
formulation 
Excipents
1:1
INITIAL 0.06 0.03 0.03 0.03 0.01 0.16
40
°
C
/ 7
5%
R
H 1M 0.06 0.03 0.03 0.03 0.01 0.16
2M 0.06 0.03 0.03 0.03 0.01 0.16
3M 0.06 0.03 0.03 0.04 0.01 0.17
1M 50°C/90%RH 0.06 0.03 0.03 0.03 0.01 0.16
Mycophenolat
e sodium+All
coating
formulation
Excipents
(seal &
enteric) 1:1
INITIAL 0.04 0.03 0.02 0.01 0.01 0.11
40
°
C
/ 7
5%
R
H
1M 0.04 0.03 0.02 0.01 0.01 0.11
2M 0.04 0.03 0.02 0.01 0.01 0.11
3M 0.04 0.03 0.02 0.01 0.02 0.12
1M 50°C/90%RH 0.04 0.03 0.02 0.02 0.01 0.12
Standard Impurities and Limits
IMPURITIES LIMITS
Impurity A Not more than 0.15%
Impurity B Not more than 0.15%
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Impurity C Not more than 0.15%
Impurity D Not more than 0.15%
Impurity E Not more than 0.10%
Total impurities Not more than 0.5%
OBSERVATION AND CONCLUSION
All the excipients used in the Drug-Excipients compatibility study were found to be 
compatible and the Impurities were within the limits. Hence further formulation development
studies are proceeded.
Characteristic of the formulation Trails F1, F2, F3 & F4
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PARTICLE SIZE DISTRIBUTION
FORMULATION  TRIAL -F1
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S.No PARAMETERS F1 F2 F3 F4
1. Bulk density (g/ml) 0.47 0.46 0.47 0.48
2. Tapped density (g/ml) 0.59 0.57 0.57 0.57
3. Carr’s index (%) 20.34 19.29 17.54 15.78
4. Hausner’s ratio 1.26 1.23 1.21 1.18
5. Flow property Poor Fair Fair Good
S.NO Sieve Analysis
Cumulative % of drug release
F1 F2 F3 F4
1. # 40 mesh retention 30.00 28.00 27.00 27.00
2. # 60 mesh retention 55.00 43.00 44.00 45.00
3. # 80 mesh retention 68.00 56.00 58.00 58.00
4. # 100 mesh retention 79.00 74.00 75.00 74.00
5. # PAN 100.00 100.00 100.00 100.00
Mycophenolate Sodium Delayed-Release Tablets 360mg
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OBSERVATION
The Carr’s  index  and the Hausner’s  Ratio  indicated that  the blend has  poor flow
characters. To understand the powder behaviour the batch was taken further for compression.
It was observed that the blend had formed a cake in the feed frame and there were
weight variations due to non uniformity of the powder flow. 
CONCLUSION
It  was  planned to  increase the binder  concentration for  better  compressibility and
increase the lubricant to improve flow property. 
FORMULATION TRIAL -F2
Physical parameters observation for core tablet:
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PARAMETERS SPECIFICATION OBSERVATION
Appearance White  to  Off  white  color,
circular  shape,  biconvex
uncoated tablets plain on both
side.  
White  to  Off  white  color,
circular  shape,  biconvex
uncoated  tablets  plain  on  both
side.  
Target weight 560.00 mg 560.00 mg
Average weight 560.00 mg ± 2.0 % +1.32 % to  -1.41%
Uniformity  of
weight
Average weight ± 4.0% +3.21 % to  -2.96%
Diameter 11.5 ± 0.2mm 11.51 to 11.52 mm
Thickness 5.70 ± 0.2mm 5.69 to 5.72 mm
Hardness 40 to 100 N 44.2 to 68.9 N
Disintegration Time NMT 15 minutes 20 minutes  04 seconds 
Friability NMT 1% w/w 0.14%
OBSERVATION
                          The Carr’s index and the Hausner’s Ratio indicated that the blend has
fair  flow characters.  To understand the  powder  behavior  the  batch  was taken  further  for
compression. 
It was observed Disintegration time more than 20 minutes.
 CONCLUSION
    It  was planned  to  increase  the disintegrating agent  concentration for  improve
disintegration.
FORMULATION TRIAL- F3
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Physical parameters observation for core tablet:
PARAMETERS SPECIFICATION OBSERVATION
Appearance White  to  Off  white  color,
circular  shape,  biconvex
uncoated tablets plain on both
side.  
White  to  Off  white  color,
circular  shape,  biconvex
uncoated  tablets  plain  on  both
side.  
Target weight 560.0 mg 560.0 mg
Average weight 560.0 mg ± 2.0 % +1.21 % to  -1.82%
Uniformity  of
weight
Average weight ± 4.0% +2.9 % to  -3.15%
Diameter 11.5 ± 0.2mm 11.52 to 11.55 mm
Thickness 5.70 ± 0.2mm 5.68 to 5.73mm
Hardness 40 to 100 N 45.3 to 64.5 N
Disintegration Time NMT 15 minutes 18 minutes  45 seconds 
Friability NMT 1% w/w 0.12%
OBSERVATION
                        The Carr’s index and the Hausner’s Ratio indicated that the blend has
fair  flow characters. To  understand the powder  behavior  the  batch  was  taken  further  for
compression. 
It  was observed Disintegration time more than 18 minutes. Compare with previous
trial same problem identified.
CONCLUSION 
It  was  planned  to  replace  following  disintegrating  agents  Croscarmellose  sodium
instead of crospovidone and maize starch instead of pregelatinised starch. 
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FORMULATION TRIAL -F4
Physical parameters observation for core tablet:
PARAMETERS SPECIFICATION OBSERVATION
Appearance White  to  Off  white  color,
circular  shape,  biconvex
uncoated tablets plain on both
side.  
White  to  Off  white  color,
circular  shape,  biconvex
uncoated  tablets  plain  on  both
side.  
Target weight 560.0 mg 560.0 mg
Average weight 560.0 mg ± 2.0 % +1.25 % to  -1.95%
Uniformity  of
weight
Average weight ± 4.0% +2.91 % to  -3.15%
Diameter 11.5 ± 0.2mm 11.52 to 11.55 mm
Thickness 5.70 ± 0.2mm 5.68 to 5.76 mm
Hardness 40 to 100 N 46.2 to 64.5 N
Disintegration Time NMT 15 minutes 6 minutes 20 seconds 
Friability NMT 1% w/w 0.18%
OBSERVATION
                       The Carr’s index and the Hausner’s Ratio indicated that the blend has
good flow characters.
Physical parameters of core tablets passed in all specification limits. 
CONCLUSION 
Next trial planned to increase the batch size of TRIAL-F4 formula and optimize the
seal coating formula by various weight buildups.
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FORMULATION TRIAL- S1
Physical parameters observation for seal coated tablet: 
S.NO PARAMETERS SPECIFICATION OBSERVATION
1. Description of tablets White  to  off  white  color,
circular  shape,  and
biconvex seal coated tablets
plain on both sides.
White  to  off  white  color,
circular  shape,  and
biconvex  seal  coated
tablets plain on both sides.
2. Target weight 574.00 mg  574.0 mg
3. Average weight 574.00 mg ± 2.0 % +1.45 % to  -2.02%
4. Uniformity of 
weight. Average weight ± 4.0%
+3.11 % to  -3.21%
5. Diameter 11.55 ± 0.2 mm 11.48 to 11.58 mm
6. Thickness 5.82 ± 0.2mm 5.81 to 5.84 mm
7. Disintegration Time  NMT 15 minutes 6 minutes 30 seconds.
OBSERVATION
                     Physical parameters of seal coated tablets passed in all specification limits. But
2.5% weight buildup of seal coating formed an irregular thin layer in core tablet. It was not
sufficient to protect the core tablet from moisture absorption during enteric coating process.
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FORMULATION TRIAL -S2
Physical parameters observation for seal coated tablet:
S.N
O PARAMETERS
SPECIFICATION OBSERVATION
1. Description of 
tablets
White  to  off  white  color,
circular  shape,  and
biconvex  seal  coated
tablets plain on both sides.
White  to  off  white  color,
circular shape, and biconvex
seal  coated  tablets  plain  on
both sides.
2. Target weight 576.00  mg  576.0 mg
3. Average weight 576.00  mg ± 2.0 % +1.44 % to  -1.98%
4. Uniformity of 
weight. Average weight ± 4.0%
+3.10 % to  -3.24%
5. Diameter 11.6 ± 0.2 mm 11.59 to 11.64 mm
6. Thickness 5.8 ± 0.2mm 5.78 to 5.81 mm
7. Disintegration Time NMT 15 minutes 7 min  52 sec 
OBSERVATION 
              Physical parameters of seal coated tablets passed in all specification limits.  In this
Seal coated tablets at the 2.86% weight buildup has laminated the core tablet properly.
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FORMULATION TRIAL -S3
Physical parameters observation for seal coated tablet:
S.NO PARAMETERS SPECIFICATION OBSERVATION
1.
Description of 
tablets
White  to  off  white  color,
circular  shape,  and
biconvex  seal  coated
tablets plain on both sides.
White  to  off  white  color,
circular  shape,  and
biconvex  seal  coated
tablets plain on both sides.
2. Target weight 577.00  mg  576.8 mg
3. Average weight 577.00  mg ± 2.0 % +1.44 % to  -1.99%
4. Uniformity of 
weight. Average weight ± 4.0%
+3.12 % to  -3.23%
5. Diameter 11.6 2± 0.2 mm 11.6 to 11.66 mm
6. Thickness 5.82 ± 0.2mm 5.78 to 5.86 mm
7. Disintegration Time NMT 15 minutes 15 min  52 sec 
OBSERVATION
                         In this Seal coated tablets at the 3.04% weight buildup has laminated the core
tablet properly. But disintegration time was more than 15 minutes.
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FORMULATION TRIAL-S4
Physical parameters observation for seal coated tablet:
S.N
O PARAMETERS
SPECIFICATION OBSERVATION
1. Description of 
tablets
White  to  off  white  color,
circular  shape,  and
biconvex seal coated tablets
plain on both sides.
White  to  off  white  color,
circular  shape,  and
biconvex seal coated tablets
plain on both sides.
2. Target weight 578.00  mg  578.2 mg
3. Average weight 578.00  mg ± 2.0 % +1.42 % to  -1.62%
4. Uniformity of 
weight. Average weight ± 4.0%
+3.08 % to  -3.18%
5. Diameter 11.6 5± 0.2 mm 11.64 to 11.70 mm
6. Thickness 5.83 ± 0.2mm 5.79 to 5.84 mm
7. Disintegration Time NMT 15 min 26  min  52 sec 
OBSERVATION
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                         In this Seal coated tablets at the 3.21% weight buildup has laminated the core
tablet properly. But disintegration time was more than 26 minutes.
CONCLUSION
                 Seal coating of the  TRIAL-S2  sample tablets compiled with the all
specification limits. Next trial planned to increase the batch size of TRIAL-S2 and optimize
the enteric coating formula by various weight buildups.
FORMULATION TRIAL-E1
Physical parameters observation for enteric coated tablet:
S.NO PARAMETERS SPECIFICATION OBSERVATION
1. Description of tablets
Peach color, circular shape,
and biconvex enteric coated
tablets plain on both sides.
Peach color, circular shape, 
and biconvex enteric coated 
tablets plain on both sides.
2. Target weight 626.00 mg 626.00 mg
3. Average weight 626.00 mg ± 2.0 % +1.83 % to  -1.91%
4. Uniformity of weight. Average weight  ± 4% +3.24 % to  -3.08%
5. Diameter 11.7 ± 0.2mm 11.69 to 11.74 mm 
6. Thickness 5.9 ± 0.2mm 5.86 to 6.02 mm
7. Disintegration Time   
a) 0.1M HCL –               No
crack should be observed in
2 hours.
b) PH 6.8 phosphate buffer- 
Disintegration NMT 45 
minutes.
a) 0.1M HCL–                   
crack observed in 56  minutes 
30 seconds  .
b)  Not performed.
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Observation
                        8.68% weight buildup enteric coated tablets failed in Disintegration test at 0.1 
M Hydrochloric acid – crack observed in 56 minutes and 30 seconds.
FORMULATION TRIAL-E2
Physical parameters observation for enteric coated tablet:
S.NO PARAMETERS SPECIFICATION OBSERVATION
1. Description of tablets
Peach color, circular shape, 
and biconvex enteric coated 
tablets plain on both sides.
Peach color, circular shape, 
and biconvex enteric coated 
tablets plain on both sides.
2. Target weight 631.00 mg 631.00 mg
3. Average weight 631.00 mg ± 2.0 % +1.7 % to  -1.98%
4. Uniformity of 
weight. Average weight  ± 4%
+3.41 % to  -3.52%
5. Diameter 11.75 ± 0.2mm 11.71 to 11.82 mm 
6. Thickness 5.95 ± 0.2mm 5.94 to 6.08 mm
7. Disintegration Time  a) 0.1M HCL–                    
No crack should be observed 
in 2 hours.
b) PH 6.8 phosphate buffer - 
Disintegration NMT 45 
a) 0.1M HCL –                   
crack observed in 1 hour 
35minutes 45 seconds.
 b) Not performed
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minutes.
OBSERVATION
9.55% weight buildup enteric coated tablets failed in Disintegration test at 0.1 M 
Hydrochloric acid – crack observed in 1 hour 35 minutes 45 seconds.
FORMULATION TRIAL-E3
Physical parameters observation for enteric coated tablet:
S.NO PARAMETERS SPECIFICATION OBSERVATION
1. Description of tablets
Peach color, circular shape, 
and biconvex enteric coated 
tablets plain on both sides.
Peach color, circular shape, 
and biconvex enteric coated 
tablets plain on both sides.
2. Target weight 636.00 mg 636.00 mg
3. Average weight 636.00 mg ± 2.0 % +1.81 % to  -1.95%
4. Uniformity of weight. Average weight  ± 4% +3.31 % to  -3.11%
5. Diameter 11.8 ± 0.2mm 11.81 to 11.84 mm 
6. Thickness 6.0 ± 0.2mm 5.94 to 6.08 mm
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7. Disintegration Time      
a) 0.1M HCL–                   No
crack should be observed in 2
hours.
b) PH 6.8 phosphate buffer - 
Disintegration NMT 45 
minutes.
a) 0.1M HCL–                   
No crack observed in 2 
hours.
 b) PH6.8 phosphate buffer- 
21 minutes 33 seconds to 24 
minutes 56 seconds.
OBSERVATION
   10.42% weight buildup enteric coated tablets compiled within the all 
specification limits.
FORMULATION TRIAL-E4
Physical parameters observation for enteric coated tablet:
S.NO PARAMETERS SPECIFICATION OBSERVATION
1. Description of tablets
Peach color, circular shape, 
and biconvex enteric coated
tablets plain on both sides.
Peach color, circular shape, and 
biconvex enteric coated tablets 
plain on both sides.
2. Target weight 641.00 mg 641.05 mg
3. Average weight 641.00 mg ± 2.0 % +1.78 % to  -1.85%
4. Uniformity of weight. Average weight  ± 4% +3.23 % to  -3.44%
5. Diameter 11.85 ± 0.2mm 11.82 to 11.87 mm 
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6. Thickness 6.05 ± 0.2mm 6.01 to 6.11 mm
7. Disintegration Time    
a) 0.1 M Hydrochloric acid 
– No crack should be 
observed in 2 hours.
 b) PH 6.8 phosphate buffer 
- Disintegration NMT 45 
minutes.
a) 0.1 M Hydrochloric acid –       
No crack observed in 2 hours.
 b) PH 6.8 phosphate buffer - 
53 minutes 30 seconds to 56 
minutes 45 seconds.
OBSERVATION
                         11.28% weight buildup enteric coated tablets failed in disintegration test in PH 
6.8 phosphate buffer-observed more than 56 minutes 45 seconds.
FORMULATION TRIAL-E5
Physical parameters observation for enteric coated tablet:
S.NO PARAMETERS SPECIFICATION OBSERVATION
1. Description of tablets
Peach color, circular shape, 
and biconvex enteric coated 
tablets plain on both sides.
Peach color, circular shape, and 
biconvex enteric coated tablets 
plain on both sides.
2. Target weight 646.00 mg 646.00 mg
3. Average weight 646.00 mg ± 2.0 % +1.81 % to  -1.95%
4. Uniformity of weight. Average weight  ± 4% +3.31 % to  -3.11%
5. Diameter 11.8 ± 0.2mm 11.81 to 11.84 mm 
6. Thickness 6.0 ± 0.2mm 5.94 to 6.08 mm
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7. Disintegration Time   
a) 0.1 M Hydrochloric acid 
– No crack should be 
observed in 2 hours.
 b) PH 6.8 phosphate buffer -
Disintegration NMT 45 
minutes.
a) 0.1 M Hydrochloric acid – No 
crack observed in 2 hours.
 b) PH 6.8 phosphate buffer - 
56 minutes 20 seconds to 1 hour 
10 minutes 35 seconds.
OBSERVATION
12.15% weight buildup of enteric coated tablets failed in disintegration test in PH 
6.8 phosphate buffer-observed more than 1 hour 10 minutes 35 seconds.
CONCLUTION
Enteric coating of the TRIAL-E3 sample tablets compiled with the all specification
limits. This trial sample tablets compare with innovator sample Dissolution profile (CDP).
DISSOLUTION PROFILE IN PH 6.8 PHOSPHATE BUFFER
INNOVATOR
 VSTRIAL-E3
Time
Innovator- 
Myfortic 360 TRIAL-E3
0 0.00 0.00
10 1.98 10.20
20 30.94 53.27
30 69.91 95.33
45 97.23 99.47
60 99.58 99.83
Dissimilarity factor & Similarity factor
F1 Limit ( 0 to 15) 18.20
F2 Limit ( 50 to 100) 31.53
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CONCLUSION 
Dissolution rate of TRIAL-E3 was found to be more when compared with the 
Innovator product. Initial dissolution rate of the test product was found to be much faster than
that of the innovator product. It was planned to increase the binder in various ratios was taken
in TRIAL-E3 formula to reduce dissolution rate to match with Innovator product dissolution 
profile.
PHYSICAL  PARAMETERS  FOR  COMPARABLE  DISSOLUTION
PROFILE TRIALS (CDP)
PARAMETERS
OBSERVATION
D1 D2 D3 D4
Core Tablet
Average weight +1.19 % to  -1.74% +1.23 % to  -1.89% +1.21 % to
-1.53%
+1.25 % to
-1.95%
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Uniformity  of
weight +2.60 % to  -3.11% +2.75 % to  -3.43%
+2.31 % to
-3.03%
+2.91 % to
-3.15%
Diameter 11.51 to 11.55 mm 11.51 to 11.53 mm 11.51 to 11.54 mm 11.52 to 11.55 mm
Thickness 5.68 to 5.76 mm 5.68 to 5.76 mm 5.69 to 5.72 mm 5.68 to 5.76 mm
Hardness 49..5 to 66.3 N 43.2 to 68.4 N 48.2 to 65.2 N 54.2 to 69.9 N
Disintegration Time 6 minutes 50 sec 7 min 30 second 08 min 55 sec 10 min 04 second
Friability 0.23% 0.18% 0.16% 0.12%
Seal coated Tablet
Average weight +1.37 % to  -1.86% +1.45 % to  -1.86% +1.51 % to
-1.68%
+1.44 % to
-1.98%
Uniformity  of
weight +3.12 % to  -3.14% +3.26 % to  -3.21%
+3.23 % to
-3.14%
+3.10 % to
-3.24%
Diameter 11.59 to 11.62 mm 11.59 to 11.61 mm 11.58 to 11.63 mm 11.59 to 11.64 mm
Thickness 5.75 to 5.81 mm 5.78 to 5.82 mm 5.79 to 5.80 mm 5.78 to 5.81 mm
Disintegration Time 8 min  30 sec 9 min  40 sec 10 min  55 sec 11 min  52 second
Enteric coated Tablet
Average weight +1.66 % to  -1.85% +1.68 % to  -1.57% +1.73 % to
-1.86%
+1.81 % to
-1.95%
Uniformity  of
weight +3.27 % to  -3.32% +3.36 % to  -3.43%
+3.29 % to
-3.21%
+3.31 % to
-3.11%
Diameter 11.79 to 11.85 mm 11.77 to 11.83 mm 11.78 to 11.81 mm 11.79 to 11.84 mm
Thickness 5.94 to 6.05 mm 5.96 to 6.04 mm 5.98 to 6.03 mm 5.94 to 6.08 mm
Disintegr
ation
Time 
0.1M HCL Passed Passed Passed Passed
PH 6.8
PHO4
Buffer
26 min  20 sec 28 min 40 sec 31 min 15 sec 34 min 54 second
DISSOLUTION PROFILE IN PH 6.8 PHOSPHATE BUFFER
INNOVATOR
 VSTRIAL-D1
Time
Innovator- 
Myfortic 360 TRIAL-D1
0 0.00 0.00
10 1.98 8.56
20 30.94 48.67
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30 69.91 92.21
45 97.23 99.17
60 99.58 99.65
Dissimilarity factor & Similarity factor
F1 Limit ( 0 to 15) 16.21
F2 Limit ( 50 to 100) 36.20
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0 0.00 0.00
10 1.98 5.83
20 30.94 42.82
30 69.91 86.33
45 97.23 99.02
60 99.58 99.81
Dissimilarity factor & Similarity factor
F1 Limit ( 0 to 15) 15.81
F2 Limit ( 50 to 100) 43.60
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0 0.00 0.00
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10 1.98 3.91
20 30.94 38.87
30 69.91 81.21
45 97.23 98.46
60 99.58 99.78
Dissimilarity factor & Similarity factor
F1 Limit ( 0 to 15) 9.59
F2 Limit ( 50 to 100) 46.50
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DISSOLUTION PROFILE IN PH 6.8 PHOSPHATE BUFFER
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0 0.00 0.00
10 1.98 2.03
20 30.94 28.45
30 69.91 66.42
45 97.23 97.68
60 99.58 99.76
Dissimilarity factor & Similarity factor
F1 Limit ( 0 to 15) 7.16
F2 Limit ( 50 to 100) 62.92
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CONCLUSION
TRIAL-D4 drug release profile was found to be satisfactory and comparable with that
of  Innovator  product.  This  is  also confirmed by dissimilarity factor and similarity factor.
Hence it was decided to pack the tablets in the proposed packaging method (Alu-Alu Blister).
This packed sample tablets were loaded for stability assessment in 50°C/90%RH (stressed
condition) for 1 month and at 40°C/75%RH (accelerated conditions) for 1 month.
STABILTY STUDIES
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STABILTY STUDIES 50°C/90% & RH 40°C/75% RH
TEST NAME LIMIT INITIAL 1 MONTH
Description of 
tablets
Peach color, circular shape, and 
biconvex enteric coated tablets plain 
on both sides.
50°C/
90%RH
40°C/75%R
H
Avg. wt (mg)
636.00 mg ± 2.0 
%
+1.66 % to  -1.85% +1.75 % to  -1.87% +1.68 % to
-1.84%
Hardness (N) 40 to 100 N 66.4 to 78.5N 65.5 to 77.8N 67.2 to 79.9N
Thickness (mm) 6.0 ± 0.2mm 5.94 to 6.05 mm 5.95 to 6.04 mm 5.96 to 6.05mm
Disintegr
ation 
time
0.1M HCL No crack should be
observed in 2 hours
Passed Passed Passed
PH6.8 PHO4
Buffer
NMT 45 minutes. 34 min 54 sec 33 min 40 sec 34 min 25 sec
Dissolution Profile
in
PH6.8 PHO4 Buffer
Time Interval %Drug Release
10 2.03 2.01 1.98
20 28.45 29.55 30.21
30 66.42 67.33 67.51
45 97.68 97.52 97.56
60 99.76 99.68 99.73
Assay 95 – 105 %
   99.65 99.57 99.62
Known   impurity NMT 0.2%    0.16     0.11     0.17
Unknown 
Impurity NMT 0.15%    0.02     0.01     0.02
Total Impurity NMT 1.0 %    0.18     0.12     0.19
CONCLUSION
         The 1 month stability data at  stressed condition showed no characteristic
changes when compared to the initial  results  which indicate the product is stable.  The 1
month stability at accelerated condition was also found to be within the specified limits. The
stability study loaded at stressed condition for 1 month reveals that the product is stable.
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SUMMARY AND CONCLUSION
SUMMARY    
Among the various routes of drug delivery system, Oral route is the oldest and most
common  route  of  drug  administration.  In  oral  administration,  tablet  is  one  of  the  most
preferred dosage forms because of its ease of manufacturing, convenience in administration,
accurate dosing and higher stability compared with oral liquids.
Mycophenolate sodium delayed-release tablets are an enteric formulation of 
mycophenolate sodium that delivers the active moiety mycophenolic acid. Mycophenolic 
acid is an immunosuppressive agent. Mycophenolic acid is an uncompetitive and reversible 
inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de 
novo pathway of guanosine nucleotide synthesis without incorporation to DNA. Because T- 
and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of 
purines, whereas other cell types can utilize salvage pathways, MPA has potent cytostatic 
effects on lymphocytes.
The  project  work  entitled  “Formulation  Development  and  Evaluation  of
Mycophenolate Sodium 360mg Delayed-Release Tablets” was carried out in the study. The
study was  mainly focused  on  the  optimization  of  the  formulation  to  meet  the  reference
product  characteristics,  based on the excipients  of  reference product,  the excipients  were
selected for Drug Excipient compatibility study trials. The binary mixtures were filled in vials
and closed with bromo butyl rubber stoppers & crimped with tear off clear lacquer aluminum
seals and charged at 50°C/90% RH and 40°C/75% RH conditions. All the excipients used in
the Drug-Excipients compatibility study were found to be compatible with API.
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The  development  was  initially  started  with  various  formulation  trials  by  wet
granulation method were formulated and evaluated to make a comparable product with the
reference product.
In  formulation  TRIAL-F3 formulated by  hand  granulation,  was  found  that  the
disintegration time more than 18 minutes. Hence a next formulation TRIAL-F4 was planned
to replace following disintegrating agents Croscarmellose sodium instead of crospovidone
and maize starch instead of pregelatinised starch. 
 TRIAL-F4 blend has good flow characters and physical parameters of core tablets
passed in all specification limits. Next trial planned to increase the batch size of TRIAL-F4
formula and optimize the seal coating formula by various weight buildups.
In seal coating optimization sample was collected from the coating pan in various
weight buildups.  TRIAL-S2 (2.86% weight buildup) sample tablets compiled with the all
physical  parameter  of  seal  coating specification limits.  Next  trial  planned to increase the
batch  size  of  TRIAL-S2 and  optimize  the  enteric  coating  formula  by  various  weight
buildups.
In enteric coating optimization sample was collected from the coating pan in various 
weight buildups. TRIAL-E3 (10.42% weight buildup) sample tablets compiled with the all 
physical parameter of enteric coating specification limits. This trial sample tablets compare 
with innovator sample Dissolution profile. 
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Dissolution rate of TRIAL-E3 was found to be more when compared with the 
Innovator product. Initial dissolution rate of the test product was found to be much faster than
that of the innovator product. It was planned to increase the binder in various ratios was taken
in TRIAL-E3 formula to reduce dissolution rate to match with Innovator product dissolution 
profile.
In TRIAL-D4 drug release profile was found to be satisfactory and comparable with 
that of Innovator product. This is also confirmed by dissimilarity factor and similarity factor. 
Hence it was decided to pack the tablets in the proposed packaging method (Alu-Alu Blister).
TRIAL-D4  Alu-Alu  blister  packed  sample  tablets  were  loaded  for  stability
assessment  in  50°C/90%RH  (stressed  condition)  for  1  month  and  at  40°C/75%RH
(accelerated conditions) for 1 month. 
The 1 month stability data at  stressed condition showed no characteristic  changes
when  compared  to  the  initial  results  which  indicate  the  product  is  stable.  The  1  month
stability at accelerated condition was also found to be within the specified limits. The stability
study loaded at stressed condition for 1 month reveals that the product is stable. 
CONCLUSION
TRIAL-D4 formulated tablets formula finalized, after passing of bio-equivalence and
stability. The formulated tablets have to be studied for physico-chemical characteristics and
stability for 6 months. Also the formulated tablets are to be submitted for bio-equivalence
study with reference listed drug.
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ABBREVIATIONS
R&D : Research and Development
RLD : Reference Listed Drug
Ph.Eur. : European Pharmacopoeia
BP : British Pharmacopoeia
USP : United State Pharmacopoeia
COA : Certificate Of Analysis
DMF : Drug Master File
IPC : In-Process Containers
CDP : Comparative Dissolution Profile
MS : Manufacturer specification
MPA
MPS
:
:
Mycophenolic Acid
Mycophenolate sodium
MPAG : Mycophenolic Acid Glucuronide
HPLC : High Pressure Liquid Chromatography
LOD Loss On Drying
FBD : Fluidized Bed Drier
API : Active Pharmaceutical Ingredient
NLT : Not Less Than
NMT : Not More Than
IMPDH   : Inosine Monophosphate DeHydrogenase
RMG : Rapid Mixer Granulator
RM : Raw Material
BCS : Biopharmaceutical Classification System
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